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ABSTRACT
DETERMINATION OF THE BIOLOGICAL FUNCTIONS OF UNDEFINED DOMAINS OF
VEEV NSP2
Andrew Michael Skidmore
April 9, 2021
Alphaviruses are positive sense, single strand, RNA viruses. These viruses occur
on every populated continent. Alphaviruses are divided into two clades, the New-World
and Old-World viruses. The New-World viruses include Eastern (EEEV), Western
(WEEV), and Venezuelan equine encephalitis viruses (VEEV), and cause neuroinvasive
disease. The Old-World viruses include Chikungunya (CHIKV) and Ross River viruses
(RRV), and typically cause multijoint arthralgia. There are currently no approved antiviral
therapeutics or vaccines for any alphavirus, making them a high priority for antiviral drug
design and discovery. A benzamidine inhibitor (ML336) of VEEV was characterized, and
determined to inhibit replication of VEEV RNA during infection of BHK-21 cells, a
fibroblast model. This activity was due a loss of synthesis of new viral RNA. This
compound had no effect on RNA synthesis in uninfected cells, making it a promising
target for therapeutic development. The inhibitory activity of ML336 was highly specific
for VEEV, having no effect on RNA synthesis of CHIKV. A potential interaction between
ML336 and the VEEV nsPs was examined, but these results were inconclusive. ML336
and related compounds were used to generate resistant mutant VEEV. These isolates
were sequenced and it was revealed that mutations were concentrated in a region of
nsP2 of unknown function. Analysis of these mutant viruses revealed delayed growth,
RNA synthesis, and translation of viral proteins in BHK cells. There was also a growth
delay seen in SH-SY5Y cells, a model of neuronal infection. These findings indicate that
this region of nsP2 is likely involved in RNA synthesis of VEEV, and shows promise as a
target of antiviral drug development.
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CHAPTER 1
INTRODUCTION
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Alphaviruses are positive sense, single stranded, RNA viruses in the family
Togaviridae, which are classified as members of the domain Riboviria1. The alphaviruses
currently encompass more than thirty members that infect a wide range of host and
vector species, both terrestrial and aquatic. These viruses are widely dispersed
geographically as well, with at least one alphavirus being present on every populated
continent23–6. These viruses are currently emerging into naïve populations making them
an important group of pathogens as there are currently no treatments or vaccines for
alphaviral disease.
The geographic distribution of the alphaviruses has resulted in the historical
classification of the viruses based on where they were initially isolated. The Old-World
viruses were initially isolated in the Eastern hemisphere, primarily in Africa. The NewWorld viruses were isolated in the Americas, and have a more diverse native
distribution, with members being found from southern Canada all the way to Argentina.
These two clades are also regarded as having distinct symptoms in the host.
The Old-World viruses generally cause arthralgia and fever, with some also
causing a rash7. There is some recent evidence that Old-World members may be able to
cause encephalitis as well, with the adaptation of neurologically invasive Sindbis (SINV)
virus in the lab, as well as its association with rare cases of viral encephalitis in Europe8–
10

. Neurological invasion is a common symptom of the New-World alphaviruses, with the

three most prominent members of this clade: Eastern (EEEV), Western (WEEV), and
Venezuelan Equine Encephalitis viruses (VEEV), demonstrating high levels of
neurological pathogenicity7. Recent research has indicated that this division may be less
stringent than previously thought, as many recently discovered New-World viruses do
not cause detectable disease in humans or other host animals at all11. Additionally,
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several New-World viruses which may display pathogenicity that is more in line with that
of the Old-World viruses, such as Mayaro virus2,12.

Alphaviral Disease
The following section will discuss the diseases that are caused by alphaviruses in
the human population.
The Old-World virus of most concern is Chikungunya virus (CHIKV), which has
recently expanded into naïve populations across Asia, southern Europe, and most
dramatically in the Caribbean3–6. This has resulted in CHIKV becoming endemic in
several regions where it previously had never achieved local transmission. The primary
risk of these viruses is the sustained arthralgia that can last for months, with one study in
Mexico indicating that over a third of confirmed CHIKV cases have arthralgia twelve
months after acute disease13. Similar instances of long term pain have been seen in
other family members as well, such as Ross River virus14.
The New-World alphaviruses generally cause more severe disease than the OldWorld viruses, however the three most common (EEEV, WEEV, VEEV) are noted for
displaying a high rate of asymptomatic infection11. This asymptomatic infection rate does
vary between the three viruses and in the two primary populations of interest, equids and
humans11. Disease is also generally more severe in equid hosts than in humans7.
Disease generally reduces in severity comparing EEEV to WEEV to VEEV, with EEEV
having the highest reported rate of neurological involvement and lethality, VEEV having
the least, and WEEV falling between the two11. However VEEV has historically caused
the largest and largest number of outbreaks affecting both human and equid populations
resulting in many thousands of human cases and equid deaths11,15.
3

EEEV is the most severe of the New World alphaviruses with case fatality rates
in some cases estimated to be above 60%16 and infection results in death or permanent
neurological sequelae in a large majority of symptomatic cases17. The virus remains
uncommon in the human population, with only in a handful of reported cases every year
in the United States18. There has recently been an uptick in cases of EEEV reported to
the CDC, with almost 40 cases reported in 2019, a more than fivefold increase from
201818.
WEEV is of moderate pathogenicity, with a case fatality and rate of neurological
involvement between that of EEEV and VEEV. While the virus has caused instances of
severe human disease, its occurrence in the human population is quite low11 and has
been declining for many years since its initial discovery in the 1930s. In fact, since 1964
there have been less than 700 cases of WEEV reported in the United States, averaging
out to less than 12 cases a year19. And there has not been a reported case of human
WEEV disease in the United States since 199820.
VEEV is the least severe of the encephalitic alphaviruses. Conversely it is also
the virus of most concern for two reasons. First, unlike the other encephalitic
alphaviruses VEEV has a history of causing large outbreaks in large portions of South
and Central America, causing thousands of human cases, with hundreds of those having
neurological involvement15. Second, VEEV is also highly transmissible via the aerosol
route, making it a concern for both accidental exposure as well as purposeful misuse21.
This high level of transmissibility made VEEV a target for bioweapon by both the United
States and former Soviet Union during the Cold War, leading to its classification as a
select agent, a classification it shares with EEEV22. VEEV generally causes a mild febrile
illness, that occasionally results in encephalitic infection, with encephalitic infection
resulting in death in approximately 10% of cases7. Cases of VEEV with neurologic
4

involvement are often fatal, and those patients that do survive are likely to suffer from
long term sequelae23.
There are currently no treatments or preventive measures available for any
alphavirus, making them targets of antiviral drug and vaccine development. The
pathology of alphaviruses is outlined in Figure 1.
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Figure 1. Alphaviral disease. Alphaviruses of both the Old and New-World clades are
known to cause febrile illness in most cases, and many of these cases do not progress
further. In severe cases, the Old-World viruses can cause long lasting symptoms,
primarily a multijoint arthralgia that can last for several months. However, the Old-World
viruses are rarely fatal. Severe cases of the New-World viruses can cause multiple
neurological symptoms. In the case of neuroinvasion the New-World viruses are
frequently fatal, and survivors generally have permanent sequalae.
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Natural Transmission of the Alphaviruses
Alphaviruses are vector borne viruses that generally require the use of an
intermediate species to transmit to a naïve vertebrate host7, and this transmission cycle
is outlined in Figure 2. Due to this cycle, the viruses must efficiently infect and replicate
in multiple species. Alphaviruses infect a wide variety of both vector and hosts, and the
species infected are specific for each virus. The reservoir species for VEEV are primarily
various rodents including cotton rats24,25 Individual alphaviruses are often able to infect
multiple different vector species, with separate species being involved in endemic
maintenance and others being necessary to cause epidemic and epizootic
transmission26. Epidemic strains of VEEV have been isolated from mosquito species of
several genera including Aedes, Ochlerotatus, and Psorophora24,25. These vectors
where epidemic strains are found are commonly referred to bridge vectors, as these
species have increase promiscuity in their feeding habits, making them more likely to
infect a non-reservoir species, such as a human or an equid27–29. The feeding habits of
vector species, as well as the natural range of vector and reservoir species are the
primary determinants of the geographic range of any given alphavirus.
The virus will first enter the mosquito or other vector through a blood meal that is
taken from an infected host. The virus will then encounter the cells of the mosquito
midgut, before passing into the hoemocel, the circulatory system of the mosquito.
Eventually virus will arrive in the salivary glands where it replicates to high levels and is
transmitted to the next vertebrate host during a blood meal30,31. Not only does vector
transmission complicate control of these viruses, but infection of the mosquito is an
important selection process, and different strains of these viruses can behave differently
in the vector. In particular, epidemic VEEV strains behave very differently in the
mosquito than those are isolated from enzootic infection30–32.
7

Upon blood meal from an infected mosquito, the alphavirus is injected into the
skin of a naïve host. As these viruses have various cellular tropisms that will result in
differing pathologies, here the general series of events that will occur for the infection of
a susceptible and permissive host cell will be described.

8

Figure 2. The transmission cycle of alphaviruses. A) Alphaviruses are maintained in
nature by cycling between a host species, typically a bird or small mammal, and a
mosquito vector species. B) Spillover events often occur into livestock, which reach high
viral titers and readily transmit the virus to additional vectors. In the case of the New
World viruses this infection almost always leads to death. C) Typically, after infection of
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livestock, humans that work in close association with these animals can also be infected
by vector species. Humans are regarded as dead end hosts for VEEV. In humans these
infections may lead to disease, and, in severe cases, death.
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Alphaviral replication
After inoculation into the vertebrate host alphaviruses enter permissive and susceptible
host cells to manufacture new virions. This process is here described in detail, and a
summary can be found in Figure 4.
Receptor-mediated endocytosis
The primary mechanism by which alphaviruses enter naïve host cells is via
receptor mediated endocytosis33. There have been multiple different suggested
receptors for cellular entry33. Two important receptors are DC-SIGN and L-SIGN, which
are likely involved in the myeloid cell tropism displayed by VEEV, which is known to
infect dendritic cells early in infection34. Multiple other receptors have been found, and
continue to be found in recent work35.CRISPR has been used to great effect in the
search for additional alphaviral receptors, with Mxra8 being found to be important for
multiple alphaviurses36, and LDLRAD3 having been described as a receptor for VEEV
specifically37. Heparin sulfate has also been found to be a binding partner for some of
these viruses, and is ubiquitously expressed33. However, it has been found that viruses
that have not been adapted to cell culture have less affinity for heparin sulfate38,39,40. This
indicates that it is likely that the amount of heparin sulfate binding that has been reported
is an artifact of cell culture adaptation of virus that has been produced and expanded in
in vitro systems.
After receptor binding the alphaviruses are then transported into the cell via
clathrin mediated endocytosis4133, resulting in a virus containing endosome passing
through the stages of acidification and maturation. The New-World viruses, including
VEEV, remain in the vacuoles until they reach the endosome stage, whereas the OldWorld viruses escape from the early endosomal compartment42.
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There is some evidence that alphaviruses may demonstrate alternative entry
strategies, such as direct entry at the host cell plasma membrane4344. This has been well
characterized in CHIKV as well, with research indicating that even though an
acidification step is required, it can occur in a manner that is independent of the activity
of clathrin45. However, the importance of this entry method remains unclear.
Fusion/ Uncoating and RNA release
Fusion of the viral and host cell membranes is achieved by the activity of the E1
protein, and expression of E1 without the other glycoproteins is enough to mediate viral
membrane fusion46,47. This fusogenic activity is initially prevented by the interaction of E1
with E2, but this interaction is disrupted at low pH33,48.
After fusion the nucleocapsid core is released into the cytoplasm of the cell. The
disassembly of the nucleocapsid is enhanced by the low pH environment, which may be
caused by membrane pores induced by E14950,5152. After escape from the endosome, the
nucleocapsid interacts with ribosomes, which disassemble the capsid in a non-catalytic
manner53. This disassembly appears to be dependent on conserved sequences in the
capsid protein54. These steps have only been outlined so far using SINV and SFV.
Translation and processing of the nsPs
As positive sense, single-stranded RNA viruses, the alphavirus genome requires
no additional processing to be available as an mRNA for translation by the host cell
ribosomes. The genome has both a 5’ methyl cap and a 3’ poly A tail, allowing for
normal recruitment of initiation and elongation factors to begin translation7. The initial
step of viral replication is the translation of the nonstructural polyprotein, which contains
the proteins which are responsible for the replication of the viral RNA. The viral nsPs are
numbered in the order that they occur in the genome from 5’ to 3’, 1-4. The genomic
12

organization of VEEV can be found in Figure 4. The initial polyprotein is translated as
either nsP123 or nsP1234, depending on read through of a stop codon that may or may
not be present in the genome depending on the alphavirus in question55,56,57.
After the initial translation of these proteins, they undergo tightly controlled cleavage
events that result in the formation of multiple intermediates as well as the formation of
the final mature replicase complex nsP1/2/3/458,59. This fully cleaved, mature complex is
highly stable. Control of this cleavage process is important as it controls the levels of
viral RNA species that are present at different times during infection60,61. This cleavage
process appears to have unique regulatory features such as having morphological
cleavage recognition instead of sequence specificity62. This regulatory process is highly
important to viral biology as altering it leads to attenuation63. Proper cleavage is also
important to immune evasion, as viruses with incomplete cleavage result in alterations of
the viral RNA species prevalences, increasing Type I interferon induction as well as
sensitivity of the viruses to interferon64.
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Figure 3. The genetic structure of VEEV. VEEV has a 12kb, linear, positive-sense
genome. The genome has two open reading frames, the nonstructural and the structural.
The nonstructural open reading frame encodes the four nonstructural proteins, which are
responsible for replication of the viral RNA. The structural open reading frame encodes
for the E proteins and capsid as well as the 6K and TF proteins. The capsid and E
proteins form the structure of the viral particle.
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Viral RNA Replication
The process of viral RNA synthesis is outlined in Figure 5. To make additional
molecules of RNA genome, the virus is required to first transcribe the positive-sense
genome into negative-sense template strand. This activity is performed by the partially
cleaved polyprotein nsp123/461. However, nsP2 has protein cleavage activity which
rapidly degrades the polyprotein into its constitutive parts. This initially produces
intermediate forms of the replicase complex that are short lived and produce both
negative and positive-sense RNA60,61. The final cleavage between nsP2 and nsP3 leads
to the formation of the mature replicase complex nsP1/2/3/4 which produces only
positive-sense RNA58,59,65. This self-proteolytic behavior creates a distinct expression
profile of the viral RNA. Initially the immature forms of the complex produce higher levels
of negative-sense RNA. As the complex is processed the synthesis of negative-sense
RNA is reduced and eventually eliminated. This causes most negative-sense RNA to be
produced early in infection, as well as less negative-sense RNA being produced
overall66.Following cleavage and assembly of the mature replicase complex, RNA
synthesis converts to the synthesis of positive-sense genomic and subgenomic RNA67.
The positive-sense genomic RNA functions primarily as the genetic material of
the next generation of virus, as well as being translationally activity in the cell to produce
additional nonstructural proteins. However, recent work has indicated that the genomic
RNA may have biological functions in addition to this, as increasing the amount of noncapped genomic RNA that is produced during infection leads to a decrease in viral
fitness68. The other positive-sense viral RNA that is produced is the subgenomic RNA.
This small RNA is produced from a separate promoter and encodes for the structural
genes of the virus55.
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Localization of genome replication
Alphaviruses demonstrate a sequestration of their replication to intracellular
membranes, which is similar to other RNA viruses which also largely replicate in and on
membranous structures69–71. The alphaviruses utilize microinvaginations called
spherules69. These are sites where the viral RNA has been found to localize in infected
cells72,73. It has been confirmed in vitro that these structures contain viral RNA synthetic
activity through the use of purified spherules to synthesize viral RNA74. It has been
recently determined that the initial formation of the spherules is dependent solely on the
activity of the nsPs with no requirement for viral RNA being present75. However, the size
of the individual spherules is dependent on the length of the RNA that is transcribed
within, which appears to be a feature unique to alphaviruses76.
Spherules were initially identified on large, endosomal-like compartments in
infected cells. In several of these viruses these spherules form at the plasma membrane
and later traffic to intracellular compartments77. This localization has not yet been fully
characterized in VEEV. In vertebrate cells, the movement of the spherules away from
the plasma membrane is dependent on the activation of PI3K-Akt-mTOR, and reduction
of this activation is associated with an increased proportion of the spherules remaining at
the cellular membrane78
Translation of the structural genes
The structural genes of the alphaviruses are produced via translation of the
subgenomic RNA. The initial gene product is a polyprotein that contains the capsid, E
proteins, 6K, and TF proteins protein557. The capsid protein contains a serine protease
domain and uses this to rapidly cleave itself from the other structural genes55. The
capsid protein forms the nucleocapsid core and is responsible for binding to and
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packaging viral RNA61, this interaction is mediated by the size and charge of the RNA
molecule79. In addition to the role that it plays in virion structure, the capsid of
alphaviruses also has biological functions involved in viral pathogenesis. In the NewWorld alphaviruses the capsid protein is able to block the nuclear pores and thus
prevent the translation of new cellular protein, enhancing viral pathogenesis, cytopathic
effect, and assisting in immune evasio80,81. This protein synthesis inhibition functions in
tandem with the nsPs which actively inhibit the synthesis of cellular proteins82.
After cleavage of the capsid protein, the glycoproteins are translated into the
endoplasmic reticulum, and pass through the Golgi apparatus before being embedded
into the plasma membrane of the cell55. These proteins are also highly posttranslationally modified via glycosylation and palmitoyaltion55.
Packaging of the viral RNA and release of the virion
After translation of the structural proteins, the viral RNA must be packaged into
the virion and then released to infect new host cells. The RNA and capsid undergo
interactions due primarily to molecule size and charges, resulting in nucleocapsid like
structures occurring in the cytoplasm55,79,83. Alphaviruses bud directly from the plasma
membrane of the infected cell7. However, it is unclear how this budding process is
initiated83. It has been found that both the preformed nucleocapsid like structures and
the glycoproteins are able to drive budding83,84. However, when either of the functions
occurs independently of the other, there is a marked reduction in efficiency, indicating
that it is likely that these two mechanisms interact to allow for the maximal budding of
virions84.
Transport of the structural proteins to the plasma membrane requires the host
secretory system84. However the exact proteins that are used remain unknown84.
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Release of virions can also be inhibited by host proteins. In particular tetherin has been
shown to prevent the release of virions from infected cells84. The general replication of
alphaviruses is outlined in Figure 4 below.
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Figure 4. The replication cycle of alphaviruses. The virion enters a susceptible cell via
receptor mediated endocytosis, and due to pH changes of the endosome releases its
RNA into the cytoplasm of the host cell. The positive sense genomic RNA is first used by
ribosomes to translate the viral nsPs as a polyprotein. The polyprotein will undergo
cleavage events that control the synthesis of the viral RNA species. This RNA synthesis
19

occurs in membrane invaginations that are termed spherules. These spherules protect
the viral RNA and nsPs from detection by the host cell. Late in infection the structural
genes are synthesized. The capsid will form into nucleocapsid cores as it packages the
viral RNA, and the glycoproteins are transported to the cell membrane. The
nucleocapsid cores translocate to the cellular membrane where they bud off, collecting
their envelope and glycoproteins and forming new infectious virus.
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Figure 5. RNA synthesis of alphaviruses. This RNA synthesis activity is carried out in
spherules on the membranes of cellular organelles. After release into the cytoplasm the
genomic RNA is used to synthesize the initial nonstructural polyprotein. nsP2 initially
cleaves between nsP3 and 4 leading to nsP123/4, which synthesizes primarily negativesense template RNA. The protein undergoes rapid cleavage through intermediate states
to reach the final replicase complex nsP1/2/3/4. This complex synthesizes new positivesense genomic and subgenomic RNA and can no longer synthesize negative-sense
RNA. The genomic RNA is used to synthesize additional genomes and is packaged into
progeny virions. The subgenomic RNA is used to synthesize the structural genes that
from the new virions.
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Functions of the alphaviral nonstructural proteins
The alphaviruses make four nonstructural proteins. These proteins are
responsible for viral RNA replication as well as many other enzymatic functions. The
nonstructural proteins are also intimately involved in the pathogenesis of the
alphaviruses. The functions of these proteins will now be described in greater detail.
While the functions of the nsPs are highly conserved, differences between the Old and
New-World viruses will be indicated when necessary.
Nonstructural protein 1
NsP1 is the capping enzyme for the viral genomic RNA, and this activity occurs
independent of the activities of the other nsPs85. The activity of this protein has only
recently been examined in VEEV, having previously been studied only in Old-World
viruses. This was also the first time that each individual step, including the final guanyl
transfer, has ben detected86. The steps occur as follows. 1) The transfer of a methyl
group from S-adenosylmethionine to position N7 of a molecule of GTP is catalyzed 2)
nsP1 receives the methyl-GTP becoming guanylated, releasing pyrophosphate in the
process 3) the 7 methyl-GMP is transferred to the 5’ end of the target RNA86,87. For this
reaction to occur properly, the RNA being capped must have had its 5’ terminal
phosphate removed by nsP288 NsP1 is also responsible for the anchoring of the viral
replicase complex to cellular membranes which are the site of RNA replication, and this
activity is required for capping to be carried out as well89–91. Very recently a cryo-em
structure was published that showed how nsP1 influences the structure of the
membrane spherules and potentially controls entry and exit of materials92. NsP1 was
found to form a ring-like structure that appears to act as a gate and controls entry and
exit from the spherule92. The nsPs are also responsible for the formation of the
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spherules and this can occur in the absence of viral RNA75 however the viral RNA
determines the spherule size76.
Nonstructural protein 2
NsP2 is a multifunctional protein with many described functions and multiple
domains with discreet enzymatic activities. First, nsP2 is responsible for host cell
transcriptional shutoff in the Old-World viruses, and loss of this phenotype reduces viral
cytotoxicity80,93. In the New-World viruses this activity is instead carried out by the capsid
protein, and nsP2 is responsible for shutoff of host cell protein synthesis, and may have
a role in packaging of viral RNA80,81,94,95. In VEEV this translational shut down provides
resistance to a pre-existing antiviral state94.
There are three recognized domains in nsP2. The N-terminal regions contains a
helicase domain, and NTPase activity that serves to provide energy for the helicase96,97.
This same region also has RNA 5’-triphosphatase activity which prepares RNA for
capping, allowing for translation and packaging in virions88. The N terminal region of the
protein including the helicase domain has recently been crystalized98. The most
interesting feature was the large number of accessory domains that were present, as
these domains had not previously been predicted by structural modeling. In particular
the so called stalk domain, which based upon our own research appears to have an
important function in viral RNA synthesis66.
Large portions of the N-terminal region of nsP2 remain poorly characterized.
Studies have implicated that in VEEV this region may be important to packaging of the
viral genome95. However, in SINV this a transposon insertion approach using the
sequence for GFP found that region was involved in the cleavage between nsP2 and
nsP3, controlling the ratio of genomic and subgenomic RNA, and regulation of RNA
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synthesis99. This range of phenotypes indicates that these regions are highly important
to these viruses, but further characterization and research is needed.
NsP2 also contains a cysteine protease domain that is responsible for the
cleavage of the nsPs from the polyprotein into its constitutive members100–102. As
described earlier, this cleavage is responsible for the transition from the synthesis of
negative-sense viral RNA to positive-sense viral RNA61,103. The protease has also been
shown to target cellular proteins, a common feature of viral proteases, and this is related
to resistance to innate immune responses104.
Lastly, nsP2 contains a putative methyltransferase domain that was predicted
due to the structure of the protein102. However, it is predicted to be inactive as it lacks the
active site residue necessary for activity85. Recently though, there has been work that
indicates this domain may play a role in interferon shutoff due to its interaction with
signal transducer and activator of transcription proteins 1 (STAT1)105. This activity
appears to be mediated by enhancing the nuclear export of STAT1, which prevents the
magnification of downstream immune signaling, including the interferon response105
Nonstructural protein 3
NsP3 is poorly understood, but mutations within this protein have resulted in
defects in both negative-sense and subgenomic RNA synthesis106.
NsP3 contains a macrodomain with both adenosine diphosphate ribose (ADPr)
binding and hydrolase activity85,107108. This ADP ribosylase activity is necessary for
infection of neural cells and the hydrolase activity results in an increase in replicase
complexes109. In a SINV model, reductions in hydrolase activity led to reduced
neurovirulence while increases in ADP ribosylase activity increased neurovirulence110.
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NsP3 also contains the highly conserved alphavirus unique domain, or AUD85.
This domain is maintained across all alphaviruses85. Recent work has indicated that it
potentially has many functions in CHIKV, particularly in subgenomic RNA replication111.
Disruption of the AUD resulted in decreased infectivity, potentially due to decreased
interaction with the viral RNA and the subgenomic promoter111.
The last feature of note in nsP3 is the hypervariable domain or HVD. This domain
is so varied that it can be distinct between strains of a single viral species, such as in
VEEV112. This region is tolerant of significant mutation and even deletion, which is
unique compared to the rest of the alphaviral genome113. Natural duplications and
insertions in this region can even have positive effects on viral fitness114. The HVD is
also involved in interaction with host cell proteins, resulting in the formation of distinct
protein complexes in Old and New-World viruses115. These interactions include the
cellular machinery responsible for the formation of stress granules, which alphaviruses
utilize to their own replicative benefit116–119. These interactions are highly specific to viral
species as well, and may partially drive the differences in pathogenesis seen between
species119–121.
Nonstructural protein 4
NsP4 is produced in small amounts by most alphaviruses due to the inclusion of
a stop codon between nsP3 and nsP455,57. Altering expression levels of nsP4, either to
increase or decrease expression, decreases viral fitness, indicating that tight control of
expression is highly important122. The tight limit on expression of nsP4 is also promoted
by it being targeted by N-end rule degradation, further limiting the amount present in the
cell123.
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NsP4 is the RNA dependent RNA polymerase (RDRP) of the alphaviruses and is
active in both positive and negative-sense RNA synthesis, with the specificity being
determined by the cleavage state of the other nsPs61,85,124. NsP4 can display RNA
synthesis activity alone, but the activity is enhanced by the presence of the other
nsPs124–126.
NsP4 also has a large N terminal region that lacks predicted structure or function.
Our own work has predicted that this region is somehow involved in viral RNA synthesis,
as mutations in this region result in resistance to the effects of a drug that inhibits the
production of new viral RNA66,127. However, the function of this region remains unclear.
Work by others has also shown that mutations in this regions have a broad range of
effects on viral RNA synthesis128. This work, as well as the antiviral resistant VEEV
isolates that have been recovered in our lab127 indicate that this region plays an
important role in RNA synthesis of these viruses potentially in tandem with nsP2. This
indicates that these proteins have additional, complex interactions and roles in viral
biology that remain to be understood. The functions of the nsPs are summarized in
Table 1.
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Protein
nsP1

nsP2

Structures
methyl transferase
domain, guanyl
transferase domain,
membrane association
domains
helicase domain, ADP
binding region, cysteine
protease, methyl
transferase like domain

Functions
caps viral RNA making it
usable by ribosomes,
anchors the replication
machinery to cellular
membranes75,85–87,89–92
unwinds viral RNA for
replication, cleaves the
polyprotein into its
constitutive parts,
digests host cell
proteins61,80,81,88,93–98,100–
105

nsP3

macrodomain,
alphavirus unique
domain, hypervariable
domain

poorly described,
necessary for
replication, highly
involved in host cell
interactions85,106–
114,116,117,120,121,129

nsP4

RNA dependent RNA
polymerase domain

synthesizes new viral
RNA57,61,85,122–126,128,130

Table 1. Summary of alphavirus nonstructural protein functions
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Current state of alphaviral therapy development
Currently there are no approved therapeutics or vaccines for alphaviral disease.
The development of treatments is urgently needed due the global range of alphaviruses
and their continuous emergence into naive populations. This is compounded with the
high risk of alphaviruses expanding their geographic ranges due to climate change.
There have been many investigations into potential alphaviral therapeutics; however
thus far, none have resulted in clinically approved treatments.
Several studies have examined the efficacy of currently approved broad
spectrum antiviral treatments. Ribavirin, a common standard of care in the treatment of
viral infections, has been found to be ineffective131. Interferon α, another common
antiviral treatment, has been found to be effective in mouse models at high doses, when
it is pegylated to increase its halflife132. However, interferon treatment has severe side
effects, and is particularly noted for the neurological symptoms it induces, such as
depression133.
A recently licensed drug of interest is the broadly anti-influenza treatment
favipiravir. Created and initially tested in Japan, this is a nucleotide analogue which has
been found to inhibit the polymerase of influenza viruses134. Treatment with favipiravir is
mildly efficacious against WEEV, increasing survival in infected mice134,135. Also,
treatment with this drug during the acute phase of infection resulted in clearance of
CHIKV from infected mice, but there was no effect on the infection if treatment was
initiated in the chronic phase136. It is important to note, that this treatment was not very
efficient, requiring high doses of drug and delivery mechanisms that would be impractical
during a natural outbreak of these viurses135,137
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There have also been many other investigations into other potential treatments,
such as therapeutic antibodies, mifiprestone analogues, and antimicrobial peptides138–
140

. Promising data has come from treatment with antagonists of argonaut 2, an

important protein in RNA silencing141 and inosine-5’-monophosphate (IMP)
dehydrogenase, an enzyme involved in guanine synthesis142131143. Finally, there has
even been work that has examined the effects of compounds like β-d-N4Hydroxycytidine, which increases the mutation rate during viral RNA synthesis in an
attempt to induce damage in the genome144. However, as mentioned above, none of
these leads have led to therapies licensed for the treatment of alphaviral infection in the
clinic. Of particular interest in ongoing antiviral research is the development of viral
targets that can be perturbed by treatment, leading to the development of more specific
antiviral therapies with minimal side effects.
The development of alphaviral therapies in the Chung lab
The Chung lab has a history of antiviral drug development, and is known for the
development of high throughput screening processes for the identification and
characterization of novel therapeutic compounds127,145–147. Briefly, libraries of compounds
are screened for increases in the viability of infected cells compared to a vehicle control.
This is performed in a 384 well format allowing for rapid screening of thousands of
compounds127. Compounds that meet the threshold for effectiveness are then assayed
for antiviral effects as well as cytotoxicity, then promising compounds are further
examined for pharmacological characteristics. This results in the identification of hit
compounds which may become lead compounds themselves, or may be used to
generate additional compounds using medicinal chemistry127.
The antiviral drug discovery work using VEEV resulted in the discovery of an
initial quinazolinone hit compound that was found to be highly effective against VEEV
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with some efficacy against EEEV and WEEV as well127. Additional compounds that have
unrelated mechanisms of action were also discovered using this same process, such as
compound ML416, a pyrimidine analoge146. The initial quinazolinone compound was
then further developed in collaboration with a medicinal chemist to the current lead
compound ML33666,148. The hit compound was also used in several basic assays of
compounds functionality and it was found to act primarily early in infection. This,
combined with sequencing data from resistant viral isolates, indicated that the hit
compound, and its derivative ML336 , were potentially acting to inhibit viral RNA
synthesis in the infected cell148. The characterization of ML336 and its activity in the host
cell will be discussed at length in the following chapter. A selection of compound
structures that were used in this characterization work is included in chapter 2.
The Chung lab not only tests these compounds as potential therapeutics, but
also utilizes this expertise in antiviral drug discovery to probe viral biology. The antiviral
compounds identified and developed in this process can be used as probes to produce
mutant viruses that resist drug treatment148. These mutant isolates can then be
sequenced and used to examine previously unknown biological activities of the viruses
used. This process is described in detail in chapter 4 of this work. Where an anti-VEEV
compound was used to probe the nonstructural proteins for novel biological functions.

Objective of Dissertation
Alphaviruses are important pathogens of both human and animal hosts and are
of particular concern due their potential use in biological warfare. Several of these
viruses are also rapidly expanding into naïve populations. There are currently no
approved vaccines or antiviral strategies available for the treatment or prevention of
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these viruses. New potential therapeutics need to be characterized and further
developed. Our group has developed and begin to examine several anti-VEEV
compounds and these require more complete study to determine their mechanism(s) of
action127. Novel antiviral compounds also have the potential to be used as probes to
characterize alphaviral biology. This is primarily carried out by the isolation and
characterization of compound resistant viruses. Mutations in these viruses can be
identified127 and any alterations in the behavior of these viruses can be mapped to the
mutated region(s). These avenues of research were explored in the context of the
following aims:
1) To determine the mechanism of action of the anti-VEEV benzamidine
compound ML336.
2) To characterize the hypothetical interaction between amidine scaffold
compounds and the nonstructural proteins of VEEV.
3) To describe the biological function of the regions of nsP2 which were found to
be important to ML336 activity.

Justification
Alphaviruses are important pathogens of both humans and domesticated
animals, and the lack of therapeutic and preventative options means that there is a
significant need for research to find and characterize new potential therapeutics and
drug targets.
The design of antiviral drugs has been historically rather difficult, as the
pathogens utilize predominantly host systems for their biological processes. While there
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has been some success with antiviral development recently, these drugs often have
significant side effects making them poorly tolerated and underutilized149,150151152153.
The current lack of anti-VEEV treatments, as well as the generally poor track
record of many antiviral compounds, have led to our own interest in developing better
antiviral compounds, with a focus on alphaviruses generally and VEEV specifically. This
virus is not only a risk of natural infection, but is also a high-risk agent for misuse,
making the development of treatments high importance.
Further, there are many areas of alphaviral biology that remain poorly defined,
despite extensive study. Antiviral compounds can be used to derive treatment resistant
viruses. Those viruses that resist treatment can be sequenced for mutations in their
genomes, and then these mutants characterized by classical virological methods. This
method has the advantage of only discovering mutations that are compatible with
replication, avoiding the creation of nonviable mutants which is common in random
mutagenesis studies. With the characterization of these isolates, new information about
the function of the viral proteins and their interaction with each other and cellular
components can be gained.
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CHAPTER 2
BENZAMIDINE ML336 INHIBITS VEEV RNA SYNTHESIS

Skidmore AM, Adcock RS, Jonsson CB, Golden JE, Chung DH. Benzamidine
ML336 inhibits plus and minus strand RNA synthesis of Venezuelan equine
encephalitis virus without affecting host RNA production. Antiviral Res. 2020
Feb;174:104674. doi: 10.1016/j.antiviral.2019.104674. Epub 2019 Dec 6. PMID:
31816348; PMCID: PMC6935354.
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Overview
Venezuelan equine encephalitis virus (VEEV) is an alphavirus that is endemic to
the Americas. VEEV outbreaks occur periodically and cause encephalitis in both
humans and equids. There are currently no therapeutics or vaccines for treatment of
VEEV in humans. Our group has previously reported on the development of a
benzamidine VEEV inhibitor, ML336, which shows potent antiviral activity in both in vitro
and in vivo models of infection. In cell culture experiments, ML336 inhibits viral RNA
synthesis when added 2-4 hours post-infection, and mutations conferring resistance to
this activity occur within the viral nonstructural proteins (nsP2 and nsP4)127. This led us
to hypothesize that ML336 targets the viral replicase complex and inhibits viral RNA
synthesis. Using ML336 and structurally related compounds, we demonstrate that the
cellular antiviral activity of this antiviral scaffold correlates with inhibition of viral RNA
synthesis. However, ML336 has no effect on the RNA synthesis of the closely related
CHIKV or on cellular RNA synthesis. With a combination of fluorography, strand-specific
qRT-PCR, and tritium incorporation, we demonstrated that ML336 inhibits the synthesis
of the positive-sense genomic, negative-sense template, and subgenomic RNAs of
VEEV. In summary, ML336 and related compounds inhibit all stages of VEEV RNA
synthesis during infection, and this activity mediates the antiviral effect of these
compounds..

Introduction
Venezuelan equine encephalitis virus (VEEV) is a single-stranded, positivesense, RNA virus belonging to the family Togaviridae, which includes other medically
important mosquito-borne viruses such as Chikungunya virus (CHIKV), and Eastern and
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Western equine encephalitis viruses (EEEV and WEEV respectively)7. The encephalitic
alphaviruses, VEEV, WEEV, and EEEV, are closely related, sharing a recent common
ancestor as determined by phylogenetic analysis154. VEEV generally causes a mild
febrile disease, while approximately 1% of patients suffer from encephalitis, leading to
death in about 10% of these encephalitic patients7. Only supportive care is available for
those with VEEV infection.
Encephalitic alphaviruses have caused periodic outbreaks in the Americas
throughout the 20th century, and of these viruses VEEV has been the most significant
public health burden. Historically, large VEEV outbreaks occur about every 15 - 20
years, typically affecting thousands of equids and humans. For example, between 1962
and 1972 in Central America15, over 109,000 human cases of VEEV were reported, with
nearly 1,000 neurological cases and over 500 associated human fatalities. These
outbreaks also caused a significant burden to the agricultural industry with over 800,000
reported deaths of equids due to VEEV infection.
In addition to large natural outbreaks, VEEV poses additional threats to the
public. VEEV is classified as a Select Agent by both the Centers for Disease Control and
Prevention and United State Department of Agriculture for its historic and potential use
as a bioweapon22. There are currently no licensed treatments or vaccines for VEEV, or
any other alphaviral infection in humans. Due to the stochastic nature of VEEV
outbreaks, and difficulty in defining target groups for vaccination, therapeutics could be
crucial for control of VEEV.
A wide variety of compounds have been reported to show anti-VEEV activities.
These include mifepristone analogues, argonaute-2 antagonists, therapeutic antibodies,
compounds that induce mutations in the viral genome, and naturally expressed host
antimicrobial peptides to name a few138–140,143,155. Efforts using the broad spectrum, FDA35

approved antivirals interferon and ribavirin resulted in antiviral effects only at doses that
were higher than are clinically relevant131,132. Other discovery efforts using nucleoside
analogues or non-nucleoside analogues have shown moderate effects against
VEEV146,156. Lastly, the broadly anti-influenza drug faviprivir134,136, shows efficacy against
some alphaviruses135. However, this drug has not been tested against VEEV in a mouse
model, and its efficacy against these related viruses is poor, requiring doses of up to 400
mg/kg/day135,157
To address the unmet need for VEEV therapeutics, we employed a highthroughput, cell-based, anti-VEEV screen and discovered a novel quinazolinone hit
compound (CID:15997213)158. This compound showed significant promise as a small
molecule inhibitor of VEEV infection with an EC50 of 1.9 µM in a cell culture assay, and
100% protection of VEEV-challenged mice at a dose 50 mg/kg in a lethal VEEV infection
model127. This hit compound was then further refined using medicinal chemistry
approaches in pursuit of compounds with superior pharmacological characteristics. The
most promising of these further derived compounds was ML336, Figure 6 A.159. ML336
shows potent and specific anti-VEEV (EC50 = 32 nM) activity in vitro, and VEEV titer
reduction greater than 7.2 logs at 5 µM145,159. ML336 also effectively protected mice in a
lethal VEEV infection model, with no apparent toxicity at any of the examined doses159.
Our previous resistant mutation studies suggest the hit quinazolinone compound
and benzamidine ML336 both inhibit VEEV replication by interfering with non-structural
proteins 2 and 4 (nsP2 and nsP4) in the middle phase of replication127. NsP2 and nsP4
are essential proteins of the viral replicase complex of alphaviruses7,102,124. The incoming
viral genomic RNA (49S) is translated to form the polyprotein nsP123 and nsP4. The
polyprotein then synthesizes negative-sense RNA using the genomic RNA as the
template strand61,160, Figure 6 B. NsP123 rapidly undergoes cleavages mediated by the
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protease activity of nsP258,59, resulting in nsP1, nsP23, and nsP4, and then further into
nsP1, nsP2, nsP3, and nsP4 (nsP1/2/3/4). The mature replicase complex, nsP1/2/3/4,
synthesizes the positive-sense, 49S viral genomic and 26S subgenomic RNAs61,103. This
viral RNA synthesis by the mature replicase complex occurs in spherules, microinvaginations on intracellular organelles, in the infected cells91,161. RNA-dependent RNA
polymerase (RdRP) activity is carried out by nsP4, and nsP2 also exhibits nucleoside
triphosphatase (NTPase) activity and helicase activity during RNA synthesis, in addition
to the aforementioned protease activity for processing of the polyprotein88,96,162.
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Figure 6. Summary of VEEV replication A) The structure of the VEEV inhibitory amidine
compound, ML336, as has been previously reported. B) A summary of the RNA
replication process of alphaviruses. First, the genomic RNA (green line) is released from
the virion into the cytoplasm, where it can recruit ribosomes and be translated into the
initial polyprotein, nsP123/4. This short-lived, initial polyprotein then synthesizes
negative-sense RNA template strands (yellow line) from the positive-sense genome. The
polyprotein then undergoes self-cleavage to form the mature, stable, replicase complex,
nsP1/2/3/4, which then synthesizes additional genomic RNA (49S) as well as
subgenomic RNA (26S, blue line).
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In order to characterize the potential of viral populations to gain resistance to
these antiviral treatments, experiments were performed that isolated resistant virus from
the treated population. The locations of mutations granting resistance were then
determined using sequencing, which can provide information on both potential
mechanisms of compound action as well as potential sites of interaction between viral
proteins and the compounds. Resistance mutations to the hit quinazolinone compound
and benzamidine ML336 both map to two regions; 1) the N-terminal region of nsP2,
nsP2 mutations Y102C, D116N, E117V, E118V, and 2) the N-terminal region of nsP4, mutation Q210
in nsP4Q210R58,85,88,96,127,130,162. The ML336 resistance mutations in nsP2 were clustered in
a region that has recently been shown to be part of the so-called “stalk” domain of the
helicase domain98. An X-ray crystal structure of CHIKV nsP2 helicase domain shows
that the nsP2 Y102, D116, E117, and E118 residues are not associated with the active site or
RNA recognition domains of the enzyme. Rather, these residues are within the distal
part of a large alpha helix and flanked by smaller disordered regions. The resistance
mutations in nsP4 are also upstream of the active site of the RdRP, in a region with no
known functional activity125. Previous work in Sindbis virus indicates that the N-terminal
region of nsP4 has importance for viral RNA synthesis possibly in a protein-to-protein
interaction dependent manner; however, no clear functions have been understood163.
In this study we sought to understand how ML336 and its benzamidine
analogues inhibit VEEV replication with a hypothesis that ML336 is directly-acting on the
replicase complex and interferes with viral RNA synthesis. Our results confirm that viral
RNA synthesis is efficiently abrogated by ML336, an activity mediated through the viral
replicase complex. We found that the synthesis of all species of viral RNAs (i.e., the
genomic (49S), subgenomic (24S) positive-sense RNA, and negative sense RNA) are
inhibited by ML336, and that the RNA inhibition displayed by ML336 is maintained in a
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cell free system of viral RNA synthesis. These findings suggest that the primary antiviral
activity of ML336 is the inhibition of viral RNA synthesis during infection.

Materials and Methods
Cell culture and viral strains
Baby hamster kidney (BHK) clone 21 cells (ATCC CCL-10) and Vero 76 (African
Green monkey kidney fibroblasts) (ATCC® CRL-1587™) were maintained in Modified
Eagle’s Medium with Earle’s Balanced Salt Solution and L-glutamine (MEM-E, Corning
10-010-CV) supplemented with 10% fetal bovine serum (FBS) (Corning 35-011-CV).
Cells were maintained at 37 C in humidified incubators with 5% CO2. VEEV strain TC-83
(gift of Dr. Connie Schmaljohn, USAMRIID) was used for this study. The strain V3526
was generated from a plasmid as described previously (Chung et al., 2014). Infections
were carried out using a virus infection medium (Modified Eagle’s Medium with Earle’s
Balanced Salt Solution supplemented (Corning 15-010-CV) with 1x GlutaMAX (Gibco
35050061), 25 mM HEPES (Corning 25-060-Cl), and 10% FBS. For Chikungunya virus
(CHIKV) experiments, CHIKV strain 181/25 (BEI Resources NR-13222) was used.
V3526 experiments were carried out in an infection media that contained L-glutamine
instead of GlutaMAX (Modified Eagle’s Medium with Earle’s Balanced Salt Solution with
L-glutamine (Corning 10-010-CV), 25 mM HEPES, 10% FBS)
Immunoblot analysis
Cells were lysed using Laemmli buffer 4% SDS (RPI L22010) w/v, 20% glycerol
w/v, 120 mM Tris-HCl pH=6.8, bromophenol blue) and 42 µM of dithiothreitol (DTT Enzo:
ALX-280-001-G025)) and the homogenate was passed through a needle to shear the
DNA, with additional sonication as necessary. After denaturation at 100C for ten
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minutes, samples were loaded onto a gradient gel (4-20%, GenScript, M42012) and run
at 140 V for 90 minutes in 1X MOPS-SDS buffer (GenScript, M00138). Proteins were
transferred to a PVDF membrane (Bio-Rad 1620177). The membrane was blocked with
5% dry milk in TBS-T, and probed using antibodies for the indicated proteins. Anti-nsP2
(Clone no. 8A4B3, available from Kerafast, EUL015) was generated as a custom mouse
monoclonal antibody from GenScript using bacterially expressed recombinant nsP2
protein, used at a final concentration of 0.4 µg/mL. Beta-actin was detected using an
antibody directly linked to horse radish peroxidase (HRP) (Cell Signal 8H10D10) at a
dilution of 1:1,000. Anti-nsP2 was detected using (HRP)-conjugated rabbit anti-mouse
IgG antibody (Sigma A0168) final concentration 1:10,000. Images were developed using
ECL reagent and captured using an Azure Biosystems c300 imaging system.
Analysis of viral RNA synthesis in vivo by metabolic labelling with 3H-uridine
Cells were infected with VEEV at a multiplicity of infection (MOI) of ten on ice for
one hour; and afterwards, cells were washed with ice-cold 1X phosphate buffered saline
(PBS Caisson Labs PBL07) and transferred to a 37C CO2 incubator to initiate the
replication (T=0). At 6 hours post-infection (HPI), cells were washed and pulsed with
virus infection media containing actinomycin D (act D) (1 µg/mL, Sigma Aldrich A9415),
tritium-labelled uridine (3HU) (5 µCi/mL, Perkin Elmer NET367250), and ML336 at
various concentration for two hours. Total RNA was isolated from the cells using RNAzol
RT according to manufacturer’s instructions (Molecular Research Center RN190). Total
RNA was mixed with 10 mL liquid scintillation cocktail (BETA BLEND, MP Biochemicals
0188245004) and the radioactivity was measured using a Perking Elmer Tri-Carb 2910
TR liquid scintillation counter. For CHIKV, infection proceeded to 8 HPI for 3HU pulse
labelling. For compound treatment, ML336 dissolved in DMSO (Sigma Aldrich D8418)
was added in the 3HU labelling mixture with a final DMSO concentration of 0.25%.
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ML336 concentrations are indicated in the results section for specific experiments. For
cycloheximide (CHX) (Sigma Aldrich C7698) treatment, cells were treated with 3HU
labelling mixture containing CHX with a final concentration of 8.8 µg/mL.
Fluorography
250,000 cells were infected at an MOI of 20 with VEEV TC-83. Cells were pulsed
for the indicated times post infection with 1 µg/mL act D, 40 µCi/mL 3HU and 2.5 µM
ML336. RNA was isolated using RNAzol RT. One µg RNA was used per treatment for
the fluorgram. Fluorography was performed following a protocol published by John
Aris164.
RNA labeling of V3526 and mutant viruses
Cells were infected with VEEV V3526 at an MOI of 5 and pulsed in 2 hour
increments up to 14 hours. Later time points were also collected at 18, 24, 30, and 40
HPI. Peak RNA synthesis was found to occur between 14 and 18 HPI (data not shown).
To compare the effectiveness of the compound, cells were infected at an MOI of 3 and
allowed to proceed to 13 HPI before pulsing with 1 µM ML336 or an equivalent volume
of DMSO. RNA was collected and radioactivity was detected as described above.
Strand-specific quantitative real-time PCR (qRT-PCR) of VEEV RNA
Detection of positive and negative sense, genomic viral RNA was carried out
using a strand-specific qRT-PCR method adapted from Plaskon et al165. Briefly, cDNA
was generated using tagged primers for detecting positive-sense and negative-sense
RNA. The generated cDNA was then used in qRT-PCR using TaqMan chemistry
(Applied Biosystems TaqMan gene expression master mix ThermoFisher 4369016) with
a strand-specific primer set. A fluorescent probe was used for both analyses. The primer
sequences are given in the following table. Lowercase sequences are additional
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sequence added for primer identification, sequences in italics are specific for viral RNA,
and sequences in bold were used to identify only those cDNA sequences that were
produced due to primer binding. All primers and probes were custom generated by IDT.
Primer
nsP1 positive
Tag
nsP1 negative
Tag
nsP1 positive
FWD
nsP1 positive
REV
nsP1 negative
FWD
nsP1 negative
REV
nsP1 probe

Sequence
GGCAGTATCGTGAATTCGATGCCTGACCTGGAAACTGAGACTATG
GGCAGTATCGTGAATTCGATGCGGCGACTCTAACTCCCTTATTG
aataaatcataa CTG ACC TGG AAA CTG AGA CTA TG
aataaatcataa GGC AGT ATC GTG AAT TCG ATG C
aataaatcataa GGC GAC TCT AAC TCC CTT ATT G
aataaatcataa GGC AGT ATC GTG AAT TCG ATG C
/56-FAM/TCC GTC AAC /ZEN/CGC GTA TAC ATC CTG /3IABkFQ

Enrichment of viral replicase complexes from infected cells
VEEV replicase complexes were isolated according to the protocol published by
Barton et al166. Cells were infected with VEEV TC-83 at 10 MOI and incubated for 6
hours. Then, cells were washed with ice-cold, sterile PBS and the cells were incubated
in hypotonic RS buffer (10 mM NaCl, 10 mM Tris-HCl, pH7.8) supplemented with
Protease inhibitor cocktail III, 30µL per 20x106 cells, (Research Products International
P50700-1) on ice for 15 minutes. Cells were scraped into buffer and thoroughly
homogenized using a Dounce homogenizer. Nuclei were removed by centrifugation at
900 x g for 10 minutes at 4 °C. Supernatant containing the cytoplasmic fraction was
transferred to microcentrifuge tubes and centrifuged at 15,000 x g for 20 minutes at 4 °C.
The supernatant (S15 fraction) was removed and pellets (P15 fraction) were suspended
in RS buffer supplemented to 15% glycerol for storage at -80 °C.
In vitro viral RNA synthesis assay
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VEEV viral RNA synthesis assay was adapted from Barton et al166. Ten
microliters of P15 fraction enriched for VEEV viral replicase complexes, which is
equivalent of approximately 1.25 x 106 infected cells, was combined with a same volume
of a RNA synthesis mix (100 mM Tris-HCl pH 7.8, 100 mM KCl, 20 µg/mL act D, 20 mM
DTT, 10 mM creatine phosphate, 50 µg/reaction creatine phosphokinase, 4 mM of ATP,
GTP, and UTP, 20 µM CTP, 12 mM MgCl2) (nucleotides from NEB N0450S) on ice and 1
µL of SUPERaseIn RNase inhibitor (Ambion AM2694 ), 5 µg of yeast tRNA (Ambion
15401011), and 5 µCi of [α-33P]-CTP (Perkin-Elmer NEG608H) were added per reaction.
After an incubation at 37 °C for 90 minutes, RNA was isolated from each reaction using
RNAzol RT and RNA mini prep kit columns (Zymo Research R2052) according to
manufacturer’s instructions, with an additional wash step before elution. For compound
addition, ML336 was added to reaction mixtures before incubation at 37 °C at the
indicated concentrations. The final DMSO concentration was 0.25%.
Autoradiography of viral RNA
After extraction of viral RNA from the in vitro reactions, the RNA was mixed 1:1
with a glyoxal loading buffer/dye with ethidium bromide (Ambion AM8551) and denatured
at 50 °C for 30 minutes. Samples were chilled briefly and loaded for RNA
electrophoresis. RNA electrophoresis was performed through a denaturing agarose gel
containing 0.8% agarose, 1X MOPS (Quality Biological 351-059-10), and 2.2 M
formaldehyde. Electrophoresis was performed at 60 V for 70 minutes, then the gels were
rinsed in nuclease-free water once and treated with 0.1N NaOH for 40 minutes at room
temperature with continuous rocking. Gels were neutralized in 20X saline-sodium citrate
(SSC) buffer (3 M NaCl, 300 mM trisodium citrate, pH7.0) for 40 minutes. RNA was
transferred to a neutral nylon membrane (GE Nytran 10416296). The RNA on the
membrane was then UV cross-linked for 5 minutes at 4 mW/cm2. Autoradiograms were
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developed using a phosphor screen (Kodak K screen 1707843) and documented using a
Pharos FX plus (BioRad). Densitometry analysis was performed using Fiji image
analysis software167.
Cell-based anti-VEEV assay
Anti-VEEV activity of compounds was measured using a cell-based CPE assay
as previously described158. Briefly, Vero 76 cells seeded in a 96 well plate were infected
with VEEV TC-83 at an MOI of 0.05 in the presence of test compounds, highest
concentration of 50 µM, serially diluted 1:2 with a total of eight concentrations, lowest
concentration 400 nM. Infected cells were incubated for 48 h and cell viability, protection
from VEEV-induced CPE, was measured using CellTiter-Glo (Promega G7570). EC50
was calculated with a 4-parameter logistic model (XLfit, IBDS).
Statistics
Statistics were performed in GraphPad Prism version 9. Unless otherwise
indicated significance was calculated using ANOVA with Dunnett corrections for multiple
comparisons. All graphs use the mean value, with error reported as standard deviation.

Results
VEEV viral RNA production peaks at 6-8 hours post infection.
To determine the optimal timepoint to examine the inhibitory effects of ML336 on
viral RNA synthesis, we first measured the rate of VEEV viral RNA synthesis over the
course of infection using metabolic labeling of RNA. After BHK21 cells were infected with
VEEV TC-83 at an MOI of 10, the synthesis of viral RNA was tracked in two-hour
increments beginning at 2 HPI by pulsing with 3HU in the presence of act D, which
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allowed us to detect only the synthesis of viral RNA by inhibiting cellular RNA
transcription from DNA templates. Using this assay, we found that VEEV RNA synthesis
was detectable at 2 HPI, and continued until 18 HPI Figure 7 A. VEEV RNA synthesis
reached its peak between 6 and 8 HPI and began to decrease at 10 HPI. There is no
significant difference between the three pulses from 4-10 HPI. So any of the three pulses
should allow for strong detection of viral RNA synthesis. The 6-8 HPI pulse was selected
due to a balance of length of the experiment, as well as the higher magnitude displayed
in this assay.
We measured expression of nsP2 as a marker for the viral replicase complex
over the course of infection by immunoblotting. Detectable amounts of nsP2 were
detected at 4 HPI, and the expression peaked at 8 HPI, which is consistent with the
timeline of viral RNA synthesis Figure 7 B. Later time points were selected due to
previous knowledge about the kinetics of nsP2 in our lab. These data together indicate
that the greatest level of RNA synthesis of VEEV is from 6-8 HPI. Based on this result,
we chose the 6-8 HPI time point for subsequent experiments for viral RNA synthesis
assays.
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Figure 7. VEEV RNA synthesis peaks at 6-8 HPI.
A) BHK 21 cells were infected with VEEV as described in the Materials and Methods of
this chapter and treated with act D and 3HU to selectively label newly synthesized viral
RNA. Total RNA was isolated and subjected to liquid scintillation counting. The amount
of label detected is reported as counts per minute (CPM) per microgram of isolated
RNA. NC is an uninfected negative control collected at 18 hours. Bars represent two
biological replicates from one representative experiment of two. Error bars indicate
standard deviation. B) BHK 21 cells were infected with VEEV and total cell lysate was
used for immunoblotting to detect nsP2. Beta-actin is included as a protein loading
control. Image is from one representative experiment of three.
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Antiviral activities of ML336 and derivatives correlated with their inhibition of viral
RNA synthesis.
Based on our previous findings127, we hypothesized that the primary antiviral
mechanism of the benzamidine scaffold, including ML336, is inhibition of viral RNA
synthesis. To test this hypothesis, we chose to examine the RNA synthesis inhibition
activities of an array of structurally analogous compounds (Table 1) based around the
ML336 amidine scaffold Figure 8159. Multiple compounds have been developed using the
base structure of ML336, with the pursuit of further improvements to both efficacy and
pharmacokinetics, this optimization is pursued for every potential lead therapeutic
compound that is discovered through the high throughput screening process. Each of
these compounds has been found to be variously effective at inhibiting VEEV induced
CPE. If the efficacy of this range of compounds at inhibiting VEEV induced CPE and
RNA synthesis corelate, it indicates that RNA synthesis inhibition is a feature of the more
general benzamidine scaffold and not unique to ML336. This also strengthens the
hypothesis that RNA synthesis inhibition is a major contributor to the antiviral activity of
the benzamidine compound family. ML416, which has an antiviral mechanism that is
independent of viral RNA synthesis and is structurally distinct, was used as a control for
comparison146. We also included our initial hit compound from our high throughput study,
CID15997213127.
Nine compounds with 50% cytopathic effect (CPE) inhibitory concentrations
(EC50-CPE) ranging from 0.1 μM to greater than 50 μM were tested in the 3HU labeling
assay159. Cells infected with VEEV TC-83 at an MOI of 10 were treated with each
compound at 1 µM at six HPI and their RNA synthesis inhibitory activities were
compared with their EC50-CPE. The concentration was held constant instead for example
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using the IC50 of each compound so that each compounds efficacy could be directly
compared. Using the middle efficacious concentration of each compounds would not
allow for variation between the measurements, and the correlation could not be
determined. Each activity was quantified as percent inhibition compared to the DMSOtreated control. While ML416 did not show any RNA synthesis inhibitory activity as
expected, each of the compounds showed various amounts of reduction of viral RNA
synthesis Figure 8. Importantly, we found a trend that compounds that were more potent
in the CPE-bases assay were generally more efficacious as inhibiting RNA synthesis,
R2= 0.42 p=0.059, as measured by the incorporation of 3H-uridine into viral RNA. This
experiment was performed from 6-8 HPI as this was found to be the time of maximal
RNA synthesis by the virus. At this time post infection, and at the MOI that was used, the
virus has already entered the cell and performed the activities of early infection (i.e.
receptor binding, endocytosis, release of the viral RNA into the cytoplasm) and the initial
translation and processing of the nsP polyprotein. Thus, the reduction in viral RNA
synthesis that is seen to occur after treatment with these compounds is likely to occur
independently from these other early infection processes. This indicates that the antiRNA synthesis activity of the benzamidine family is likely mediating the antiviral effects
that that occur during infection with VEEV.
Several compounds that were tested in the assay were strongly inhibitory of RNA
synthesis but had little effect on cell viability, such as CMP3. While none of these
compounds were cytotoxic, CC50 > 50 µM159, it is possible there are some off target
effects that make the compounds less protective.
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Figure 8. Compounds derived from ML336 also inhibit viral RNA replication.
BHK 21 cells were infected with VEEV as described and infection proceeded to 6 HPI.
Cells were pulsed for 2 hours with actD, 3HU, and one of the compounds of interest at 1
µM or DMSO vehicle control. The amount of 3HU incorporated into the viral RNA was
quantified by liquid scintillation counting. The percentage of label that was incorporated
compared to a DMSO control, with 100% inclusion resulting in 0% inhibition, and 0%
inclusion resulting in 100% inhibition. This data was compared to the percent protection
from TC-83-induced CPE in a cell-based assay. Percent protection is the percent of
viable cells after infection compared to DMSO vehicle control treatment. R2=0.42
p=0.059, calculated using linear regression in GraphPad Prism. ML416 was included as
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an outgroup, as it is effective at inhibiting VEEV induced CPE but is known to function by
an RNA synthesis independent mechanism. Each point represents three biological
replicates and the experiment was repeated twice (Exp 1 and Exp2). Compound IDs are
found in Table 2.
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Number

Compound
ID

Percent
Protection
From CPE

CMP1
CMP2
CMP3
CMP4
Hit
CMP6
CMP7
ML416
CMP9
ML336

CB10002593
CB10002582
CB10002510
CB10002491
CB10000905
CB10002462
CB10002594
CB10002681
CB10002704
CB10002700

5.2
11.3
21.0
51.9
61.2
65.3
73.9
95.1
96.5
106.6

Percent
RNA
Inhibition
Exp 1
42.5
68.0
84.3
80.4
90.0
94.9
101.6
-20.0
110.4
112.7

Table 2. Chemical IDs and effectiveness in the CPE and RNA inhibition assays.
Compound ID numbers are the same as the structure IDs available in PubChem.
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Percent
RNA
Inhibition
Exp 2
10.7
59.7
97.8
82.0
91.9
87.9
99.2
102.6
103.0

Number

Compound ID

CMP1

CB10002593

CMP2

CB10002582

CMP3

CB10002510

CMP4

CB10002491

Hit

CB10000905

CMP6

CB10002462

CMP7

CB10002594
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Structure

ML416

CB10002681

CMP9

CB10002704

ML336

CB10002700

Table 3: Structures of the selected compounds
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The anti-RNA synthesis activity of ML336 is VEEV-specific and has no effect on
cellular RNA synthesis.
Having determined that ML336 and related compounds are able to inhibit VEEV
RNA synthesis during active replication, we sought to further characterize this anti-RNA
synthesis activity. First, we determined the potency of ML336 against VEEV viral RNA
synthesis. Cells were infected with VEEV strain TC-83 and treated with 3HU and various
concentrations of ML336 from six to eight HPI as described in the Materials and
Methods. The amount of 3HU incorporated into the total isolated RNA was measured
and a dose response curve was generated to calculate the IC50 Figure 9 A. ML336
showed strong, dose-dependent inhibition of viral RNA synthesis activity with an IC50 of
1.1 nM with a standard deviation of 0.7 nM. At 40 nM, ML336 decreased viral RNA
synthesis to 7% of the control. These data indicate that VEEV RNA synthesis is
efficiently inhibited by ML336. Also, ML336 was efficacious at inhibiting viral RNA
synthesis at the EC50 determined by the cell-based assay.
Previously, we determined that compounds based around the ML336
benzamidine scaffold had no antiviral effect on CHIKV in cell culture using the CPE
assay145. If the antiviral effect of this compound is mediated by the inhibition of viral RNA
synthesis, then CHIKV will also resist this activity. We measured the inhibition of RNA
synthesis by ML336 treatment on CHIKV using the 3HU assay. As can be seen in Figure
9 B, ML336 had no effect on CHIKV RNA synthesis even at 4 µM (P > 0.22, ANOVA),
the highest concentration we tested, and 4000-fold higher than the IC50 value of the
compound against VEEV in this assay, compared to an untreated positive control.
To measure the effect of ML336 on cellular RNA production, uninfected BHK
cells were incubated with ML336 at the indicated concentrations or with a DMSO control
in the presence of 3HU without act D Figure 9 C. Overall, ML336 did not show an
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inhibitory effect on cellular RNA synthesis. A small decrease in cellular RNA synthesis
was detected only at the highest concentrations of ML336, 50 µM and 25 μM, which are
over 20,000-fold higher than the IC50 value, indicating that the inhibitory activity of
ML336 against cellular RNA synthesis is negligible at working concentrations.
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Figure 9. The RNA synthesis inhibition of ML336 is highly specific and has no effect on
cellular RNA synthesis.
A) BHK 21 cells were infected with VEEV as described and cells were pulsed from 6-8
hours post infection with act D, 3HU, and ML336 at the indicated concentrations. Each
point represents three biological replicates, error was calculated as the standard
deviation. Dose-response curves were generated using four parameter curve fitting in
Graph Pad Prism software 9th edition. B) BHK 21 cells were infected with CHIKV at an
MOI of 10 and infection proceeded as for VEEV. Cells were treated with the indicated
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amounts of ML336. U is an uninfected control. Graph is of one representative
experiment of two total experiments, each point represents three biological replicates,
and error is standard deviation. C) Uninfected BHK 21 cells were treated with VEEV at
the indicated concentrations or DMSO control. Cells were pulsed for 2 hours with
compound and 3HU. NL is an unlabeled control reaction. Graph is of a single
representative experiment of two experiments, points each represent three biological
replicates, and error is standard deviation.
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Viral isolates that can replicate in the presence of ML336 resist the RNA synthesis
of inhibition of the compound.
As previously mentioned, we have isolated several strains of VEEV that resist
treatment by either our initial hit compound127 or ML336, by serially passaging in the
presence of the compound or by direct sequencing in the presence of the compound.
These resistant viruses have mutations mapped in the N-terminal regions of nsP2 (e.g.,
nsP2Y102C mutation) or of nsP4 (e.g., nsP4Q210K mutation)127. Either of these mutations is
enough to cause resistance in isolation, i.e. only one of the two mutations is required for
compound resistance. We hypothesized that if inhibition of viral RNA synthesis is the
primary outcome of ML336 treatment, then these mutants would maintain levels of RNA
synthesis similar to the parental virus in the 3HU incorporation assay. We introduced the
mutations that were found in the mutant strains into the plasmid encoding the full,
infectious genome of V3526 and then produced the mutant virus strains in the presence
of the initial hit compound at a concentration of 5 µM127. After determining that maximum
levels of RNA synthesis occurred at 14 HPI (data not shown) we performed a metabolic
labeling experiment in the same manner as described in our methods.
As expected, viral RNA synthesis of the parental V3526 was sensitive to
treatment with ML336, and viral RNA synthesis was fully abrogated at 5 µM Figure 10.
Comparatively, the mutant viruses showed varying levels of sensitivity to ML336. The
nsP2Y102C mutant showed 76.2 % RNA synthesis compared to the control and nsP4Q210K
mutant showed no inhibition compared to a vehicle control. This result clearly shows that
the compound-resistant mutant viruses are able to overcome the RNA synthesis
inhibitory effects of ML336. Our data so far support the hypothesis that ML336 is a viral
RNA synthesis inhibitor that acts through nsP2 and nsP4.
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Figure 10. ML336 resistant mutations grant resistance to RNA synthesis inhibition.
Mutations were introduced to the clonal VEEV V3526 backbone and these mutant
viruses were subjected to the RNA synthesis inhibition assay as described at a
concentration of 5 µM ML336. The amount of 3HU label was quantified by liquid
scintillation counting. The amount of incorporated label was divided by the amount
present in the DMSO treated control and multiplied by 100 to yield the percent of RNA
synthesis. Graph is from data from two experiments, each with three biological
replicates. Error is reported as standard deviation.
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ML336 inhibits both positive and negative RNA synthesis of VEEV.
During infection with VEEV, several RNA species are generated by the virus
which have distinct functions. We next sought to determine if ML336 specifically targeted
the synthesis of one or more of these RNA species. To determine if ML336 inhibits either
positive or negative-sense RNA production, we used a strand-specific qRT-PCR165.
VEEV-infected cells were treated either with ML336 or DMSO at 4 HPI, and the copy
numbers of positive and negative-sense viral RNA were quantified and compared. This
earlier time point was selected as the rate of negative-sense RNA production decreases
later in infection. As shown in Figure 11 A, the control group (DMSO-treated) had almost
a 1 log increase in the amount of positive-sense RNA and an approximately half log
increase of negative-sense RNA during the period of 4 to 6 HPI.
In the presence of ML336, however, the amount of positive- and negative-sense
viral RNA did not increase at all, which demonstrated the inhibition of both positive- and
negative-sense viral RNA synthesis by ML336. The presence of ML336 did not affect the
ratio of positive to negative-sense RNA. The copy number of positive-sense RNA was
10,000-fold higher than that of the negative-sense RNA at all time points and in both
ML336 treated and untreated conditions. This difference in the levels of the RNA species
is consistent with findings previously reported in alphaviruses by others168. These results
show that the synthesis of both the positive and negative-sense strands of VEEV RNA
was affected by ML336.
ML336 inhibits the RNA synthesis by the mature replicase complex.
For alphaviruses, the majority of viral RNA synthesized in the infected cells is
positive-sense RNA (See Figure 11 A) and the synthesis of positive-sense RNA is
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dependent on the amount of negative-sense genomic RNA (Figure 5)85; therefore, the
inhibition of negative-sense RNA synthesis would result in the inhibition of positivesense RNA synthesis . To determine if the inhibition of viral positive-sense RNA
synthesis by ML336 is due to the inhibition of negative-sense RNA synthesis, we sought
to test the effect of ML336 on positive-sense viral RNA synthesis alone.
The alphavirus negative-sense RNA is produced only by the newly translated,
short-lived, polyprotein, nsP123/4 or nsP1/23/461,160. Therefore, it has been wellestablished that inhibition of translation (e.g., treatment with cyclohexamide) prevents
the production of the negative-sense RNA by nsP123/4, which allows us to measure the
positive-sense specific RNA synthesis by the pre-formed, mature, viral replicase
complex85,169.
We measured viral positive-sense RNA synthesis using our 3HU labelling assay
in the presence of cyclohexamide (CHX), a translation inhibitor, and evaluated the effect
of ML336, Figure 11 B. Treatment with CHX showed no significant difference in the total
viral RNA production compared to the vehicle control. This data indicates that the
majority of viral RNA that was being synthesized at this time was positive-sense RNA,
which is consistent with data reported by others85 as well as our real-time PCR
experiments shown in Figure 11 A. Importantly, we found that the treatment of VEEVinfected cells with ML336 completely abrogated viral RNA production even in the
presence of CHX. This shows that ML336 inhibited the synthesis of viral RNA generated
by the mature replicase complex (i.e., positive-sense RNA), and the inhibition of the
negative-sense viral RNA synthesis is not required for ML336 to inhibit positive-sense
viral RNA synthesis.
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ML336 inhibits the synthesis of both genomic and subgenomic VEEV RNA.
Having determined that ML336 inhibits the synthesis of positive-sense VEEV
RNA, we sought to determine if the inhibition of the positive-sense RNA strand was
specific to either the genomic or the subgenomic RNA. Alphaviruses synthesize two
species of positive-sense RNAs, the genomic RNA (49S), which is packaged into
progeny virions and is used for translation of the nonstructural polyprotein, and the
subgenomic RNA (26S), which is responsible for the production of the structural genes.
The expression of these two RNAs is controlled by the amount of polyprotein that has
been synthesized, and the current cleavage state of the polyprotein61,103,160.
To understand whether the inhibition of viral RNA synthesis was specific to
genomic (49S) or subgenomic (26S) viral RNA, we analyzed the viral RNAs that were
produced in the presence or absence of ML336 using fluorography of 3HU-labeled viral
RNA. As Figure 11 C shows, the addition of ML336 to VEEV-infected cells at any time
post-infection up to 8 hours completely abrogated synthesis of both genomic and
subgenomic viral RNA. This indicates that addition of ML336 inhibits the synthesis of
both 49S and 26S viral RNA in cells.
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Figure 11. ML336 inhibits all stages of VEEV RNA synthesis.
A) Strand-specific qRT-PCR was performed on RNA isolated from TC-83 infected BHK
21 cells that were either treated with ML336 at 5 µM or DMSO vehicle control. RNA copy
number was measured by using a standard curve with known viral RNA copy numbers.
Each point represents a mean and standard deviation from three biological replicates. B)
Metabolic labeling of VEEV RNA was performed as before using act D and 3HU, with
data collected by liquid scintillation counting. Cells were labeled from 6-8 HPI. CHX:
cyclohexamide. Graph is from one representative experiments with three biological
replicates per treatment. Error is reported as standard deviation. C) A representative
fluorogram after treatment with ML336. Cells were treated with ML336 at 2.5 µM or
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DMSO at the time points indicated and then the RNA was visualized by treatment with a
scintillant and exposure to X-ray film as described in the materials and methods. 1 µg of
RNA was used per lane. G: genomic RNA, SG: subgenomic RNA.
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ML336 inhibits VEEV RNA synthesis in a cell-free system.
The work outlined here implies that ML336 and related compounds function to
inhibit VEEV infection by interfering with the synthesis of viral RNA. And this activity is
specific to viral RNA and has minimal effect on cellular RNA synthesis (Figure 10).
Further, it is known that the replication of viral RNA is carried out directly by the virally
derived replicase complex58–61. This catalytic activity is also maintained by purified
protein124,125 Additionally it has been previously found that viral isolates that resist
treatment with these antiviral compounds have mutations in the N terminal region of
nsP2 and nsP4148. When taken altogether, this led to our hypothesis that ML336 and
related compound were likely to be directly interacting with the viral nsPs to mediate
their anti-VEEV activities. Currently there has been no successful expression of the full
length nsP2 protein of any alphaviruses, and the other nsPs are also known to be
difficult to ectopically. This limited our abilities to examine a potential interaction between
these proteins and ML336. This led to our use of a so-called cell-free RNA synthesis
assay.
The cell-free RNA synthesis assay was developed for alphaviruses many years
ago and uses fractioned cellular components as both enzyme and template to generate
viral RNA in the absence of complete, living cells166170. While this method does not
completely remove cellular components from the assay, it greatly limits the amount of
cellular proteins present, and is currently the best that can be done to isolate and
examine the activities of the nsPs directly. The use of the P15, or membranous fraction,
provides both template and polymerase to examine viral RNA synthesis. P15 fraction
isolated from VEEV-infected cells was incubated with ribonucleotide substrates (e.g.,
ATP, GTP, and UTP) and radioactive CTP in the presence of ML336 or DMSO, then the
in vitro synthesized viral RNA was analyzed on denatured agarose gels.
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As shown in Figure 12 A, while there was no radiolabeled RNA produced by the
P15 fraction of uninfected cells, three distinct viral RNA bands corresponding to genomic
(49S), subgenomic (26S), and a replication intermediate, which has been previously
reported on denaturing gels 166, were present in the RNA produced with P15 from virusinfected cells. The addition of ML336 in the reaction decreased the amount of all three
RNA species in a dose-dependent manner. At ML336 concentrations greater than 200
nM, there was complete abrogation of all viral RNA synthesis. This result, complete
inhibition of viral RNA synthesis of the P15 fraction, indicated that the inhibition of viral
RNA synthesis by ML336 is independent from cellular metabolism and supported our
hypothesis that ML336 inhibits viral RNA synthesis by a direct interaction with the viral
replicase complex.
The IC50 value in this assay was then determined via optical density analysis
from three separate experiments, and was found to be 49 nM, which is similar to the
EC50 value as determined in our initial cell-based assays, Figure 12 B. This IC50 value is
higher than that seen for RNA inhibition in our 3HU incorporation assay, Figure 9 A. This
is most likely due to differences in the RNA labeling reactions. The 3HU incorporation
assay labels all of the viral RNA that is being produced in the cell. However the cell-free
synthesis assay is labeling primarily positive-sense RNA manufactured by mature
replicase complexes. This could lead to less sensitivity as ML336 also inhibits the
synthesis of negative-sense RNA.
The autoradiogram in Figure 12 A and also shows a large amount of small RNA
products being labeled that were not present in the fluorgram in Figure 11 C. This is due
to the being different ways of making and labeling RNA. The fluorgram uses total
isolated RNA from infected cells, which is made in an ideal system for the virus. The
labeling periods are also rather long allowing for highly efficient incorporation of label
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into the RNA. The autoradiogram, by contrast, is in a limited system, with minimal
resources for the replicase complex. This minimal system is probably the cause of the
increase in labeled small transcripts. These transcripts could be early terminated RNA,
RNA synthesis initiating incorrectly, or RNA in the middle of synthesis
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Figure 12. ML336 is active in a cell-free system.
The P15 was isolated from BHK 21 cells infected at an MOI of 10 with VEEV TC-83.
This material was combined with various reagents as described in the methods, with
[α33P]-CTP to label viral RNA. A) A representative RNA gel showing the results of the
labeling reaction. The 28S and 18S ribosome subunit rRNA were used as size markers.
RI: a VEEV replication intermediate; G: the VEEV genomic RNA; SG: the VEEV
subgenomic RNA. U is an uninfected control. 0 µM is a DMSO treated control. RNA
amounts were controlled by using equal numbers of infected cells (1.25 x 106) per
reaction, and total isolated RNA was used from each reaction. B) Densitometry was
performed on three images from separate experiments to quantify the amount of labeled
RNA present. These results are shown as a dose response curve. The IC50 value in this
assay was found to be 49 nM.
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Discussion
ML336 and its analogues have been discovered through medicinal chemistry
efforts originating from a quinazolinone hit compound that was identified from a cellbased high-throughput assay using live virus127. While our previous approaches using
cell-based assays and mapping of resistance mutations strongly suggested viral RNA
synthesis as the target step of this antiviral activity, the mechanism of action of the
compounds has remained unclear127,145. In this study we employed additional cell-based
and biochemical assays to evaluate the effect of these compounds on VEEV viral RNA
and host cell synthesis. Our data suggest that ML336 and related compounds inhibit
VEEV by directly preventing viral RNA synthesis via a direct interaction with the viral
replicase complex. ML336 demonstrated an efficacious inhibitory activity in both cellbased and cell-free viral RNA synthesis assays, and showed strong inhibitory activity
against the synthesis of all viral RNA species. Our data strongly support the conclusion
that the primary anti-VEEV mechanism of the amidine compound, ML336, is interfering
with viral RNA synthesis.
The inhibition of viral RNA synthesis mediated by interaction with the replicase
complex has not yet been described for any antiviral with efficacy against alphaviruses.
With regards to the molecular mechanism of these compounds, resistant mutations in
nsP2 (e.g., nsP2Y102C) indicate that this region of nsP2 may be important for sensitivity to
ML336. A homology model of VEEV nsP2 made using a recently published crystal
structure of the N terminal region of nsP2 of CHIKV with the I-TASSER protein modeling
server171–173, Figure 14, has shown that the residues that are important for sensitivity to
ML336 are located in an accessory domain to the helicase, termed the stalk domain, in
nsP298. The stalk domain is a large alpha helix that is external to the active site of the
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helicase, which may imply that this region could be involved in the protein interactions in
the replicase complex during infection.
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Figure 13. Homology model of VEEV nsP2 N terminal region.
A ribbon structure homology model of the first 465 amino acids of VEEV nsP2 was
produced using I-TASSER. This model was made possible by the recent publication of
the crystal structure of this same protein region from CHIKV by the Luo lab98 which was
used as the basis for our model. Domains are color coded. N terminal domain (red),
Stalk domain (orange), 1 B (yellow), Rec 1 (green), Rec 2 (light blue), Connector (dark
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blue). The region where our compounds are expected to bind is the stalk in the stalk
domain. The location of one of the resistance residues, Y102, is indicated with the side
chain. The ADP binding pocket is also marked.
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Our work characterizing the benzamidine compounds also has the potential to lead to
further understanding of the divergence between the New- and Old-World alphaviruses.
The Old-World alphaviruses (e.g., CHIKV) do not show susceptibility to this scaffold as it
relates to RNA synthesis inhibition. The nsP2102 residue is occupied with a tyrosine in
New-World alphaviruses (i.e., EEEV, VEEV, and WEEV); while a lysine residue occurs
at this position in the Old-World alphaviruses. This information provides insight into novel
ways in which the N-terminal regions of nsP2 and nsP4 may affect the divergent
phenotypes of the New- and Old-World viruses. Lastly, further research to understand
the mechanism of ML336 may assist in the design of new compounds that inhibit
replication of the Old-World alphaviruses.
In conclusion, we demonstrated that ML336 is a selective and potent inhibitor of
VEEV viral RNA synthesis and that the inhibition of viral RNA synthesis might be the
primary antiviral mechanism of this class of compounds. Our results strongly support
that this class of compounds has a high potential for effective antivirals for New World
alphaviruses.
Conclusions
The previously discovered antiviral compound ML336 was found to inhibit the
replication of viral RNA by VEEV. This activity appears to be mediated through domains
of currently unknown function in the N terminal regions of viral nonstructural proteins 2
and 4. Further characterization of this proposed interaction will be helpful in determining
the function(s) of this domain which is currently proposed as an accessory domain to the
helicase. We hypothesize that it will be involved in protein/protein interactions due to its
location external to the helicase active site, as well as it showing no evidence of RNA
binding activities.
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CHAPTER 3
ANALYSIS OF INTERACTIONS BETWEEN AMDIDINE COMPOUNDS AND THE VEEV
NSPS
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Overview
As outlined in the previous chapter, ML336 and related compounds mediate their
anti-VEEV activity by inhibiting viral RNA synthesis. Due to the specificity of this activity,
as well as the fact that viral isolates that resist compound treatment have mutations in
the N terminal regions of nsP2 and nsP4127, we hypothesize that ML336 and related
compounds interact with VEEV nsP2 and nsP4. To detect and characterize the
hypothetical interaction(s) between the amidine compound family and Venezuelan
equine encephalitis virus (VEEV) it is desirable to determine the location and dynamics
of this interaction. However, working with VEEV proteins in biochemical assays is
difficult due to difficulty expressing them recombinantly. This chapter outlines various
methods that were tested in an attempt to characterize this interaction, as well as the
development of a system for the ectopic expression of VEEV nsP2.

Introduction
While the mechanism of action of our amidine family anti-VEEV compounds has
been thoroughly examined, the interaction(s) between these drugs and their targets has
yet to be fully characterized. Characterizing these interactions will provide more detail
about the mechanism of action, as well as assist in the further development of this
compound scaffold. It was hypothesized that ML336 and related compounds interact
with the nsPs of VEEV. This is due to several observations. First, when viral isolates
occur that resist treatment with this compound family, the mutations that occur in these
viruses are primarily focused in nsP2 and nsP4127. This indicates that these regions and
proteins are important in mediating compound activity. Second, ML336 acts to inhibit
viral replication and CPE by interfering with viral RNA synthesis. This activity is known to
be carried out by the viral nsPs. Lastly, ML336 remains activity in a cell-free RNA
synthesis assay. While this assay does not eliminate all cellular proteins, it does
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eliminate all living cells. This indicates that the antiviral activity of this compounds is
unlikely to be dependent on cellular signaling processes.
However, the detection of these hypothetical interactions between ML36 and the
viral nsPs is difficult, as most methods of interaction detection require both large
amounts of starting material, in this case of viral protein, as well as highly pure sample.
There are often challenges in expressing eukaryotic, or in this case viral, proteins such
as insolubility, disulfide bond formation, and post-translational modification174,175176,177,
and the VEEV nsPs have been historically difficult to generate in this manner, as can be
seen in only partial expression of nsP2 that has been achieved98,102.
To date, there has been relatively little success in solving the structures of the
VEEV nsPs, which makes the prediction of binding sites and interaction using in silico
methods challenging. While the macrodomain of nsP3, and the protease of nsP2 have
solved structures102,108,178, the remaining proteins and domains have proven difficult to
work with and only recently has there been published work examining parts of their
structure. The N terminal region of nsP2 has recently been crystalized from CHIKV, and
this allowed for the development of homology models of this protein in VEEV98. A cryoem derived structure of nsP1 was also recently published in its membrane bound form92.
The crystal structure of nsP2 has paired knowledge of protein structure with previous
research that this protein contains several biologically active domains, in particular the
C-terminus contains a cysteine like protease domains, while the N terminus has helicase
and RNA binding activity88,96,162. The C-terminal region of nsP2 also contains a methyl
transferase like domain, however this domain has not been confirmed to be functional85,
however it appears to involved in innate immune signaling105. Mutations in this region
also interfere with the localization of nsP2 to nucleus179
The determination of protein function and the production of proteins for various
biochemical assays is greatly aided by the use of vector systems for the expression of
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proteins. The most common vector system is the use of specially designed strains of E.
coli that are optimized for this purpose. These systems typically utilize inducible
expression systems that can be controlled by media supplementation174. There are also
many strains available that have been optimized for the expression of difficult eukaryotic
proteins174.
With the goal of examining the hypothetical interactions between ML336 and the
VEEV nsPs, several methods of protein isolation and labeling were attempted. The
methods that were utilized were fractioning of cells and ultracentrifugation, the labeling
of proteins and tracking of interactions using Click-iT chemistry, and recombinant
expression of VEEV nsP2.
It was first attempted to purify the nonstructural proteins from infected cells.
Previous work has established that these proteins could be detected in highly purified
spherules from infected cells 74. So, we sought to enrich for this fraction from infected
cells and then determine if we could use this fraction for biochemical binding assays.
After finding little success with this approach, a recently developed chemical labeling
system referred to as Click-iT chemistry180 was utilized.
This chemistry utilizes functional groups that are essentially absent in biological
systems, azides and alkynes, to perform highly specific interactions which form covalent
linkages between these groups. These interactions can be used to label molecules for
imaging, for isolation of molecules form complex mixtures, and many other downstream
applications. Multiple types of reactions have been optimized both with and without
copper catalysis. In this instance proteins are metabolically labeled with a methionine
analogue that can be then be appended using a marker than can then be purified or
tracked with imaging techniques181182183. This system is advantageous as it can be
performed during infection easily, and depending on the method used requires minimal
protein for detection. Working with our medicinal chemist collaborator, we also obtained
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two compounds, one with efficient antiviral activity and one without, that were modified to
contain click labile functional groups. This allows for these compounds to be directly
labeled in the Click reaction and detected in a variety of ways.
While this system showed promise, being able to detect both metabolically
labeled proteins as well as specifically appended click labile antiviral compounds, these
methods were not specific enough for our needs. We detected primarily cellular proteins
after metabolic labeling, and the click labile compounds were too dispersed throughout
the cells to make colocalization with viral replication centers or proteins possible.
Lastly, an expression system was developed for nsP2 and nsP4. The work of
expressing and purifying this protein was performed iteratively, starting from attempting
to express fusion peptides of nsP2 and nsP4 in multiple orientations. It was
hypothesized that these proteins interact in the replicase complex due to resistance
mutations occurring in both of these proteins in response to treatment with the small
molecule antiviral compounds. This initial strategy eventually led to the successful
expression of the N terminal region of nsP2 using a large solubility increasing tag in a
highly specialized strain of E. coli termed Rosetta, that has been altered for the
expression of both proteins with a large number of disulfide bonds as well as for codons
that are rare in E. coli174.

Materials and Methods
Cell culture and viral strains
Baby hamster kidney (BHK) clone 21 cells (ATCC CCL-10) and Vero 76 (African
Green monkey kidney fibroblasts) (ATCC® CRL-1587™) were maintained in Modified
Eagle’s Medium with Earle’s Balanced Salt Solution and L-glutamine (MEM-E, Corning
10-010-CV) supplemented with 10% fetal bovine serum (FBS) (Corning 35-011-CV).
Cells were maintained at 37 C in humidified incubators with 5% CO2. VEEV strain TC-83
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(gift of Dr. Connie Schmaljohn, USAMRIID) was used for this study. The strain V3526
was generated from a plasmid as described previously (Chung et al., 2014). Infections
were carried out using a virus infection medium (Modified Eagle’s Medium with Earle’s
Balanced Salt Solution with L-glutamine (Corning 10-010-CV), 25 mM HEPES, 10%
FBS)
Solubilization of the P15 fraction
Cells were infected with VEEV TC-83 at 10 MOI and incubated for 6 hours. Then,
cells were washed with ice-cold, sterile PBS (Caisson Labs PBL01) and the cells were
incubated in hypotonic RS buffer (10 mM NaCl, 10 mM Tris-HCl, pH7.8) supplemented
with Protease inhibitor cocktail III (Research Products International P50700-1) on ice for
15 minutes. Cells were scraped into buffer and thoroughly homogenized using a Dounce
homogenizer. Nuclei were removed by centrifugation at 900 x g for 10 minutes at 4 °C.
Supernatant containing the cytoplasmic fraction was transferred to microcentrifuge tubes
and centrifuged at 15,000 x g for 20 minutes at 4 °C. The supernatant (S15 fraction) was
removed and pellets (P15 fraction) were used for further analysis.
To solubilize the membranes and release the viral proteins the P15 fraction was
treated with either Triton X-100 (Sigma Aldrich T-9284) (2% v/v) or sodium deoxycholate
(Sigma Aldrich 30970) (DOC) (0.5% w/v) with or without 1M NaCl at 4°C for ten minutes
with mixing at 750 RPM. The insoluble material was then removed by centrifugation at
15k x G for 20 minutes at 4C. The supernatants were then used in a cell free RNA.
Method adapted from Pietla et al74
Isolation of viral proteins via glycerol and sucrose gradients
Supernatants from DOC solubilized P15 fractions were used as the input material
for ultracentrifugation over a glycerol gradient. A discontinuous gradient was made using
three steps 15%, 23%, and 30% glycerol with 1 mM EDTA (Promega V4231) , 50 mM
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Tris-HCl pH=7.8, 0.5% DOC (w/v) and 150 mM NaCl. Samples were centrifuged at
100,000 RPM for 1 hour in a Beckmann TLA 110 rotor at 4°C. Ten fractions of 500 µL
were collected by bottom puncture and those with the highest activity as measured by
RNA synthesis assay were further separated via a sucrose gradient.
A three step discontinuous sucrose gradient was used to further separate the
fractions that were found to have RNA synthesis activity after the initial separation on the
glycerol gradient. The steps were 15%, 30%, and 60% sucrose (w/v). The samples were
centrifuged at 100,000 RPM for 6.5 hours in a TLA 110 rotor at 4°C. Ten fractions of 500
µL were collected by bottom puncture. Fractions were assayed for activity in the RNA
synthesis assay.
Isolation of viral proteins using cesium chloride
Cesium chloride is used to create continuous gradients during centrifugation, and
separates cellular components based on density rather than migration speed as
opposed to glycerol and sucrose gradients. An aqueous solution of 1.37 g/mL CsCl was
made and loaded into centrifuge tubes. The P15 from infected cells was isolated and
solubilized as described above. The samples were loaded on top of the gradient and
centrifuged at 100,000 x G for eight hours at 4°C in a Beckmann TLA 110 rotor. Ten
fractions of 500 µL each were collected by bottom puncture. Floating material that did
not enter the gradient was also collected.
Immunoblotting
The collected fractions after glycerol centrifugation were combined with Laemmli
buffer (4% SDS w/v, 20% glycerol w/v, 120 mM Tris-HCl pH=6.8, bromophenol blue) 2:1
and boiled to denature proteins. The prepared samples were loaded into gradient gels
for SDS-PAGE (GenScript M00656) and run at 150V until the dye front reached the
bottom of the gel. Protein was transferred to a PVDF membrane (BioRad 1620177)
using methanol Tris-glycine buffer (200 mM glycine, 25 mM Tris, 10% methanol v/v) for
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two hours at 20 V. Membranes were washed once with 1X TBS and blocked with 5% dry
milk in TBS at room temperature for one hour. The membrane was washed five times in
TBS-0.01% tween 20, and then stained with primary antibody overnight at 4° C. The
nsP2 monoclonal antibody was used at a final concentration of 0.4 µg/mL diluted in TBST. The membrane was then washed five times with TBS-T and stained with secondary
antibody diluted in TBS-T. Anti-mouse HRP stained the nsP2 antibody and is used at a
final concentration of 1:10,000. The secondary antibody staining was performed for one
hour at room temperature. The membranes are washed six times in TBS-T and
developed in ECL reagent for five minutes at room temperature. The images were
collected using an Azure Biosystems c300 imaging system for detection of
chemiluminescence.
Cell-free RNA synthesis assays
VEEV viral RNA synthesis assay was adapted from Barton et al166. Ten
microliters of P15 fraction enriched for VEEV viral replicase complexes, which is
equivalent of approximately 1.25 x 106 infected cells, was combined with a same volume
of a RNA synthesis mix (100 mM Tris-HCl pH 7.8, 100 mM KCl, 20 µg/mL act D, 20 mM
DTT, 10 mM creatine phosphate (Sigma Aldrich 10621714001) , 50 µg/reaction creatine
phosphokinase (Sigma Aldrich C3755-3.5KU), 4 mM of ATP, GTP, and UTP, 20 µM
CTP (NEB N0450s), 12 mM MgCl2) on ice and 1 µL of SUPERaseIn RNase inhibitor
(Ambion AM2694 ), 5 µg of yeast tRNA (Ambion 15401011), and 5 µCi of [α-33P]-CTP
(Perkin-Elmer NEG608H) were added per reaction. After an incubation at 37 °C for 90
minutes, RNA was isolated from each reaction using RNAzol RT and RNA mini prep kit
columns (Zymo Research R2052) according to manufacturer’s instructions, with an
additional wash step before elution. For compound addition, ML336 was added to
reaction mixtures before incubation at 37 °C at the indicated concentrations. The final
DMSO (Sigma Aldrich D8418) concentration was 0.25%.
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Silver stain of total protein
The fractions collected after CsCl centrifugation were mixed 2:1 with Laemmli
buffer (4% SDS (RPI L22010) w/v, 20% glycerol w/v, 120 mM Tris-HCl pH=6.8,
bromophenol blue) and boiled to denature the proteins. The prepared samples were
analyzed by SDS-PAGE in a gradient gel, run at 150 V until the dye front reached the
bottom of the gel. Gel was stained using the Pierce Silver Stain Kit (Thermo Fisher
24612) according to manufacturer’s directions. Gel was digitally scanned.
L-AHA labeling of proteins
Cells were infected with VEEV TC-83 at an MOI of ten and held on ice for one
hour. The cells were washed once with PBS and released into warm infection media.
Infection proceeded for 8 hours. The infected cells were then starved of methionine 30
minutes before labeling was begun by incubation in DMEM hi-glucose without
methionine, cysteine, or sodium pyruvate (ThermoFisher 21013024). Cells were then
treated for one hour with azidohomoalanine (Anaspec AS-63669) (L-AHA) a methionine
analog which contains an azide, at a concentration of 25 µM.
DIBO labeling of L-AHA treated cells
Dibenzocyclooctyne (DIBO) is the catalyst for copper free click chemistry. This
version of click chemistry is useful because it avoids the off target effects of copper in
cells184. For labeling of live cells, the cells are washed twice with PBS then DIBOAlexafluor 647 (ThermoFisher

C20022) in PBS was added to the wells to a final

concentration of 5 µM. The cells were rocked in the dark at room temperature for one
hour. The cells were washed twice with PBS then lysed with lysis buffer (1%SDS (w/v),
50 mM Tris-HCl pH = 8). Cells were held in lysis buffer for fifteen minutes on ice,
suspended and moved to Eppendorf tubes, then sonicated for five minutes in a water
bath sonicator. The lysate was centrifuged for five minutes at max speed at 4C to
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remove any debris. For DIBO labeling of cell lysate, DIBO-Alexafluor 647 was added to
a final concentration of 5 µM to the cell lysate. Lysate was incubated in the dark for one
hour at room temperature.
Copper containing Click-iT reaction
Cells were infected at an MOI of 10 with VEEV TC-83. Cells were held on ice for
one hour. Cells were washed once with PBS and then released into warm infection
media. Infection proceeded for 3.5 hours and the cells were methionine starved as
before. The cells were treated with L-AHA at 25 µM for four hours. The cells were lysed
as before, and the proteins were precipitated using methanol:chloroform precipitation.
The proteins were then labeled using the Thermo Click-iT (C10276) protein reaction
buffer kit according to manufacturer’s instructions. The labeled proteins were separated
by SDS-PAGE, 150V until the dye front reached the bottom of the gel, and images
collected using a BioRad Pharos imaging system.
Treatment of infected cells for fluorescent microscopy
BHK-21 cells grown on glass coverslips were infected at an MOI of 0.25 and held
on ice for 1 hour to synchronize infection. Cells were washed with PBS and warm
infection media was added to initiate infection. Infection proceeded for 5.5 hours at 37C
and 5% CO2. The media was aspirated, and the cells were pulsed with media containing
either of the two compounds at 10 µM or 0.25% DMSO vehicle control. Compounds
3260 and 3261 are derived from the amidine scaffold backbone, they differ in that they
each contain both an azide and alkyne functional group. The azide is photolabile and
used to UV fix the compounds to whatever they are bound to in the cell. The alkyne is
then used from Click chemistry. Cells were incubated for 30 minutes at 37°C 5% CO2.
The cells were washed for ten minutes in HBSS (Lonza 04-315Q). The cells were short
wavelength UV fixed for ten minutes to immobilize the compounds. The cells were fixed
in a one-to-one mix of acetone and methanol at -20°C for 20 minutes in preparation for
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an immunofluorescence assay (IFA) and to permeabilize the cells. The click reaction
was then carried out on the monolayer: 1mM CuSO4, 100 mM L-ascorbic acid sodium
salt, 20 mM Tris-HCl pH=8.5, 20 µM A647 alkyne. 300 µL of the solution was added per
well, and the plates were incubated in the dark at room temperature for 30 minutes.
Cells were washed four times with PBS and then used for antibody staining.
Staining of cells for microscopy
After the click reaction to directly detect the click labile antiviral compounds, the
cells were stained to detect VEEV nsP2 and double stranded RNA. The antibodies were
diluted into PBS with 0.1% saponin (Sigma Aldrich 47036) with 1% normal horse serum.
Anti-VEEV E protein (BEI) was used at a concentration 1:10,000, and JS1 anti-dsRNA
antibody (obtained from the lab of Dr. Nobuyuki Matoba as a human FC switched
antibody) at a concentration of 1:1000. Primary antibody staining was carried out
overnight at 4°C. The cells were washed three times with PBS-saponin and then stained
with secondary antibody in the same buffer as before. Anti-goat 555 (gift from the AbuKwaik lab) was used at a concentration of 1:1,000 to stain for E protein while anti human
488 (JIR 709-545-149) was used to stain for dsRNA at a concentration of 1:1,000.
Secondary staining was carried out at room temperature for one hour. The cells were
washed four times with PBS saponin. The cells were incubated with Hoechst stain
diluted 1:10,000 in PBS for ten minutes at room temperature. Slips were removed from
the plate and mounted on glass slides using Prolong Gold Antifade mounting medium
with DAPI (Invitrogen P36931).

Design of protein expression plasmids
Initially we deigned pET19.b plasmids that expressed fusions of the N terminal
domains of nsP2 and nsP4 in two orientations, nsP2-nsP4 and nsP4-nsP2 with a flexible
linker between the two regions, a map of one such insertion is shown in Figure 17
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(custom expression plasmids from GenScript). These constructs were insoluble. We
next attempted to express the N terminal domain of nsP2 as carried out by the Luo lab98.
Expression of the N terminal domain of nsP2 was performed using the same Pet19.b
plasmid backbone. The protein construct encoded a his tagged SUMO solubility tag,
immediately followed by the first 465 amino acids of VEEV nsP2. This construct and
plasmid backbone is found in Figure 16 (custom expression plasmids from GenScript).

Strains of bacteria used for expression
All protein expression experiments were carried out using E. coli. All
strains are based on the BL21 (DE3) strain of E. coli which contains the genes
necessary for inducible expression of protein using isopropyl-B-d1thiogalactopyranoside (IPTG). Strain BL21 (DE3) was used for expression of the
expression of the nsP2-4 fusion peptides. E. coli Rosetta (Novagen 70594, gift
from the lab of Dr. Donghan Lee) was used for expression of the N-terminal
region of nsP2.
Expression of the N terminal domain of VEEV nsP2
The expression vector was transformed into E. coli Rosetta, and then
used for protein expression. Cultures were grown at 37°C in LB broth to an
OD600 of 0.4 and induced with the addition of 1 mM IPTG. The cultures were
shifted to 18°C and then grown overnight.
Isolation of bacterially expressed proteins
The bacterial cultures were centrifuged to pellet. Three mL of cell lysis
buffer was added per gram of E. coli cell pellet (50 mM Tris-HCl pH=8, 1mM
EDTA (Promgea V4231) pH=8, 500 mM NaCl, 1 mM DTT (Enzo ALX-280-001G025))) and the bacteria were resuspended. Four microliters of 100 mM
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phenylmethylsulphonyl fluoride (PMSF), and 80 µL of ten mg/ml lysozyme were
added per gram of E. coli. This mixture was agitated for 20 minutes at 4°C. Four
milligrams of sodium deoxycholate were added per gram of E. coli and this
mixture sonicated on ice to ensure complete lysis. The lysate was centrifuged at
5000 RPM for 1 hour at 4°C in a Beckman JS-5.3 rotor. The supernatant is the
soluble fraction.
Recovery of protein from inclusion bodies to determine localization during
expression
To recover protein from the inclusion bodies, the pellet was resuspended
in 30 mL of cell lysis buffer 2 (50 mM Tris-HCl pH=8, 10 mM EDTA pH=8, 500
mM NaCl, 0.5% v/v Triton X-100), and incubated for five minutes at room
temperature in a water bath. The solution was centrifuged at 5000 RPM for
twenty minutes at 4°C and the supernatant discarded. This was repeated twice,
for a total of three washes. The pellet was then washed with 30 mL of water and
centrifuged as before.
The supernatant was discarded, and the pellet was suspended in an equal
volume of inclusion body solubilization buffer (50 mM Tris-HCl pH=8, 1mM EDTA
pH=8, 500 mM NaCl, 8 M urea, 0.1 mM PMSF freshly added) as the volume of
the soluble fraction collected. This mixture was stirred at room temperature for
one hour. Any remaining insoluble material was removed by centrifugation at
5000 RPM for twenty minutes at 4°C. This is the purified inclusion body fraction.
Purification of recombinantly expressed protein
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The expressed proteins contained histidine tags. To purify the desired
protein nickel column chromatography was used (HisPure Ni-NTA resin Thermo
Fisher, 88222). Resin was packed into a gravity column and washed and
prepared according to manufacturer’s instructions. Protein samples were
equilibrated in PBS with 10 mM imidazole. Increasing amounts of imidazole in
PBS were used to elute the protein as indicated, ranging from 30 to 310 mM.
Each elution was three resin bed volumes (3 mL of imidazole solution for 1 mL of
packed resin). All purification steps were performed at 4°C

SDS-PAGE analysis of expressed protein
Protein load was controlled based on OD600 of the bacterial sample. Sample
was suspended in 100 µL buffer per OD unit. 20 µL of sample was combined with
Laemmli buffer and separated in gradient gels. Gels were run at 150V until the dye front
reached the bottom of the gel. Gels were stained with colloidal Coomassie (BioRad
1610803)

Results
Use of purified spherules for detecting the interaction between ML336 and related
compounds with the VEEV nonstructural proteins
It has been previously shown that purified spherules from alphavirus infected
cells contain RNA synthesis activity and contain nsPs74. It was determined that the
protein contents of these spherules could be purified by centrifugation, and their protein
contents could be utilized in assays to determine the interaction of the amidine scaffold
compounds and the nsPs.
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The spherules can be isolated from infected cells by ultracentrifugation. Several
gradient materials can be used for this purpose. In the case of these experiments,
glycerol, sucrose, and cesium chloride were used. The proteins that were isolated were
assayed for activity in the cell free RNA synthesis assay to confirm that their structure
remained intact. While there was some activity maintained by the isolated protein after
the initial glycerol separation, this activity was very weak compared to the starting
material and was completely lost upon further isolation using a sucrose gradient. This
indicates that structure of the protein complex was disrupted, and they were not suitable
for further use, Figure 14 A and B. This is likely due to disruption of the proteins during
the centrifugation process. In previously published work the spherules were kept intact
during centrifugation74. The disruption of these lipid layers is likely to leave the proteins
more exposed to damage during the isolation process. Additionally a different media was
used to form the gradient, a specialized sugar called iodixanol74. This specialized media
has been used previously for the isolation of live cells185, and its particular properties
probably assisted to keep the proteins protected.
There were also issues with the ultracentrifugation being able to isolate the nsPs
to a single fraction, as shown in Figure 14 C, where nsP2 was detected in multiple
fractions after ultracentrifugation, indicating that separation across the gradient was
poor. This poor separation led to our hypothesis that separation by velocity, as in
glycerol or sucrose gradients, may not be able to separate the cell components
sufficiently in this case. These results led to our use of a CsCl gradient. This method
creates a homogenous solution that then creates a density gradient during the
centrifugation process which separates components based on their densities.
After centrifugation with CsCl most protein in the cellular extract remained
floating on top of the solution and did not enter the column, Figure 14 D. This indicates
that the proteins were contained in structures that greatly reduced their density. This
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most likely indicates that despite the initial solubilization to disrupt the lipids contained in
the extract, enough of them remained intact to interfere with the separation of the
proteins. After this was unsuccessful, other methods were examined that would allow for
marking the proteins of interest in the infected cell instead of needing to extract them.
This led to the use of click chemistry.
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Figure 14. Isolation of the nsPs from infected cells using ultracentrifugation. A) P15 from
infected cells was solubilized and separated over a stepwise glycerol gradient. After
fraction collection the RNA synthesis activity, as measured by CPM using 33P
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incorporation, was isolated in fractions four and six. B) The active fractions were then
further separated over a three-step sucrose gradient. After this further separation the
RNA synthetic activity of these fractions was lost, image from one representative
fraction. Graphs are from one representative experiment of three C) The nsPs did not
cleanly separate across a glycerol gradient. After separation across a three step glycerol
gradient, an immunoblot was performed to detect nsP2. NsP2 was detected in several
fractions, and in a pellet, P, that occur at the bottom of the centrifuge tube. Ten fractions
were collected, increasing glycerol concentration from fraction 1 to 10. Image is one
representative experiment of 2. D) A continuous density gradient made using CsCl was
also unable to separate the proteins. A solution of CsCl was generated and the
solubilized P15 fraction loaded on top. After centrifugation ten fractions were collected,
increasing density from fraction 1 to 10. Fractions collected by bottom puncture. There
was also a large amount of floating material F, that this did not enter the gradient and
held a large majority of the proteins. The proteins were also present in a third of fractions
at roughly equal level, indicating that separation was poor. Total protein was detected by
silver staining. Isolation with CsCl was only attempted once.
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The use of click chemistry to label proteins.
Initially, the labeled proteins were extracted using methanol precipitation and
then appended with fluorophore using the click reaction. Cells were infected at an MOI of
ten with VEEV TC-83 for 3.5 hours. The cells were methionine starved for 30 minutes
and then labeled with L-AHA for 4 hours. Cells were lysed and the proteins isolated
using methanol precipitation. These proteins were then analyzed by gel electrophoresis,
Figure 15 A. However, there was poor detection of viral proteins generally, and the nsPs
could not be resolved, indicating that this method was not sensitive enough to detect the
proteins of interest specifically compared to the cellular proteins. It is important to point
out that the specificity of this assay was based on the result of VEEV infection inhibiting
the synthesis of cellular proteins. However, as can be seen, there was still extensive
labeling of cellular proteins at the time point examined. Future experiments would need
to either utilize later time points in infection, or use pharmacological inhibitors of cellular
protein synthesis.
As metabolic labeling and in vitro tagging of the viral proteins was poorly
sensitive and significantly labeled cellular proteins in addition to viral proteins, it was
determined that altered antiviral compounds that already incorporated one of the
functional groups would instead be used. Compound 3260 is an effective antiviral
compound with an EC50 of 1 µM in the CPE prevention assay, compound 3261 is an
ineffective compound with and EC50 of greater than 50 µM. These compounds are
derived from the same amidine backbone as ML336. Each contains both an azide and
an alkyne moiety. The azide is photolabile and allows for the use of UV to fix the
compounds in place in the cell. This degrades the azide, and then the alkyne is usable
for click it chemistry. The advantage of this method is that these compounds are not
subject to the changing efficiencies of metabolic labeling, and the potential association of
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the compounds and the viral proteins can be observed by co-staining with antibodies
that detect the viral proteins. Two compounds were used, 3260, which is an effective
antiviral and was hypothesized to associate with the viral proteins, and 3261 which is not
an effective antiviral and was predicted to not associate with the viral proteins.
Cells were infected with VEEV, and then treated with the compounds for 30
minutes. The cells were then fixed and permeabilized, and the click reaction was
performed directly on the cell monolayers. The cells were then stained with antibodies
against E protein and dsRNA to determine the localization of replication and infection
compared to the antiviral compounds.
As can be seen in Figure 15 B, there was no significant association between
either of the compounds tested and dsRNA staining the pink staining, indicating the
labeled compounds, is distributed throughout all of the cells equally, regardless of
infections indicated by the yellow E protein or green dsRNA. The pink staining does not
associated with either of those strains significantly within infected cells. While the active
antiviral compound is expected to reduce dsRNA detection, due to the short treatment
time (30 minutes) we had hoped that the compounds would not have taken full effect
and that some viral replication would have remained active. Ultimately the only
difference between the treatments was that the effective anti-VEEV compound,
CB10003260, was able to enter cells at much higher levels compared to the ineffective
anti-VEEV compound, CB10003261, used as a negative control. Importantly, this assay
confirmed the antiviral effect of compound 3260, as the cells treated with this compound
had very little dsRNA staining, indicating an inhibition of viral RNA synthesis. And
compound 3261 did not display this effect.
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Figure 15. Use of click-iT to identify viral protein/compound interactions. A) Uninfected
and TC-83 infected cells were metabolically labeled with L-AHA to mark all newly
synthesized proteins for click it detection. Cells were infected at an MOI of ten for 3.5
hours and treated with L-AHA for 4 hours before lysis. The click it reaction was
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performed with DIBO A647 either in the live cells or on cell lysate. Cells were lysed and
proteins precipitated. Proteins were run in a gel and then imaged with a BioRad pharos
imager. Only the lysate showed significant click labeling. There was minimal detection of
viral proteins compared to cellular proteins. One representative image of two
experiments. B) Representative images of infected cells treated with click moiety
compounds. Cells were infected at an MOI of 0.25 for 5.5 hours and treated with the
indicated compounds for 30 minutes at 10 μM. Compound 3260 is active against VEEV
and enters cells. Compounds 3261 is inactive and does not. There was no significant
association between the compounds and either viral E protein or dsRNA. Representative
images of one of two experiments.
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Expression of recombinant protein for biochemical analysis
The data from the click chemistry experiments was unable to confirm the
hypothesis that the amidine antiviral compounds are associating with the nsPs of VEEV
to mediate their activity. Having gone through several methods attempting to use
proteins produced during infection, it was determined that we would attempt to
recombinantly express and purify the proteins of interest. As mentioned above, E. coli
was selected due to its ease of use and readily available reagents and genetic systems.
While it was known that expressing nsP2 in particular was likely to be difficult we
started from an atypical approach of expressing the N terminal regions of nsP2 and
nsP4 in fusion with one another. This fusion peptide was designed working under the
hypothesis that these two domains interact closely in the mature replicase complex. This
was hypothesized because of the high occurrence of compound resistant mutations in
these two regions. Assuming that the antiviral compound binds to a single location in/on
the replicase complex, for both of these regions to bind these small molecules they
would need to be in close association with one another. We thus hypothesized that
these regions are in close association, and that maintain this association in our protein
constructs would result in enhanced folding and solubility during bacterial expression.
Two fusions were created, nsP2-4 and nsP4-2. The expression of these proteins
was tested in E. coli BL21 (DE3). Maps of the protein constructs discussed here and the
plasmid backbone used are shown in Figure 16. Neither of these two fusion proteins
were able to be produced in a soluble manner, with both of them localizing to the
inclusion body fraction of the E. coli after purification. Figure 17 A shows data from the
nsP2-nsP4 fusion peptide. Various optimizations were carried out, e.g. altering the
temperature of induction and the amount of inducer added to the media, but these made
no difference in the solubility. Refolding was attempted but this was also unsuccessful.
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While the next steps were being determined, Luo group published the
crystallization of the N terminal domain of nsP2 from CHIKV, outlining the expression of
the N terminal domain of nsP2 in a soluble manner by using E. coli Rosetta and a
solubility increasing tag termed SUMO186. With their assistance, a new expression
construct was designed that incorporated their methods for expression of the N terminal
domain of VEEV nsP2. E. coli Rosetta was generously shared by the lab of Dr. Donghan
Lee, as was a plasmid for the expression of the SUMO protease for removal of the tag
during purification. As can be seen in Figure 17 B, this new construct was indeed soluble
when expressed in this strain of E. coli. And in Figure 17 C it is shown that it is also
readily purified using a Ni column for his tag purification.
Large amounts of this protein were synthesized, and then submitted to HPLC for
final purification before use in binding assays. Unfortunately, after the HPLC was
performed, there were no peaks detected. Indicating that the protein was somehow lost
during purification. This could be due to any number of factors. The protein may have an
affinity for the matrix that was used during the separation process. Granule may have
formed during the isolation process and clogged the matrix of the column. Or the protein
could have degraded over the long transit time in the column, resulting in decreased
concentration and lack of detection.

98

Figure 16. Expression constructs used for ectopic synthesis of VEEV nsP2. A) The
fusion peptide combining N terminal portions of nsP2 and nsP2. B) The SUMO tagged N
terminal nsP2 construct that produced soluble protein. C) The pET-19b vector backbone
that was used for expression, map obtained from GenScript, from which these
expression constructs were purchased.
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N-nsP2

Figure 17. The expression and purification of VEEV nsP2 in bacterial cells. A) VEEV
nsP2-nsP4 fusion protein was expressed in BL21(DE3) E. coli. The protein was
insoluble and formed inclusion bodies. MW=molecular weight, NI= non induced, I=
induced, IS= insoluble fraction, INC= inclusion bodies, S= soluble fraction. One
representative image from three experiments. B) The N terminal 465 amino acids of
nsP2 were expressed solubly using a SUMO tag. The protein expression was evenly
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split between the soluble fraction and the inclusion bodies. One representative image
from 5 expression batches. C) Soluble nsP2-465 could be purified using Ni-NTA
chromatography. Optimization of imidazole concentration was only performed once.
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Discussion
The isolation and use of viral proteins in biochemical and binding assays pose
several challenges. Primarily, these proteins can often be difficult to isolate from infected
cells as they occur at relatively low numbers, and like many proteins that are produced in
eukaryotic systems, they are often difficult to produce using vector systems. However,
based on previous work that had shown spherules could be successfully isolated from
infected cells; we attempted to isolate the VEEV nsPs from infected cells directly.
Unfortunately, this was unsuccessful.
The use of ultracentrifugation initially showed promise, as there was localization
of activity from the isolated fraction, but this activity was lost after an additional round of
purification across sucrose. Several methods were tried to improve this activity, such as
the addition of viral RNA to serve as more template in the RNA synthesis reactions,
changing the methods of RNA extraction, and altering the conditions of the synthesis
itself, such as adding different amounts of radiolabel and rNTPs. None of these
improved the activity of the fractions appreciably. While CsCl also did not result in good
separation of the protein, there are other more specialized materials that can be used to
as gradient material. One of these is iodixanol, a specialized sugar molecule that has
been previously used in the isolation of biomolecules187. Iodixanol is known to be gentle
and is even used for preparation of live cells185. Thus the use of this material may result
more preserved RNA synthesis activity and better preserve the structure of the isolated
proteins. This would likely result in better maintenance of the enzymatic activity of these
proteins, allowing for easier tracking during isolation. Gentler separation and isolation of
the target proteins would also increase the concentration of the protein isolated from
these infected cells.
As these attempts at isolating spherules proved impractical, the next attempt at
detecting the interaction between the amidine compounds and the viral nsPs was carried
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out using click chemistry. The primary advantage of this method is that the viral proteins
are labeled in the cell during infection, and that the detection of the labeled proteins is
highly specific due to use of functional groups that do not naturally occur in biological
systems. It was hoped that this experiment would result in specific labeling of viral
proteins, and that this method could then be used to directly isolate these proteins whole
cell lysate. The first attempt at this labeling, using gel electrophoresis and fluorescent
labeling detection was unsuccessful. This is due to the fact that the viral proteins were
not labeling efficiently enough to become apparent in the infected samples versus the
uninfected control cells. One way that this could be improved is to treat cells later in
infection. As time goes on, the synthesis of proteins in the cells shifts more towards the
production of viral proteins. So treatment with L-AHA later in infection should more
preferentially label viral proteins, allowing for more sensitive detection.
Due to the poor results from L-AHA labeling, alternative uses of click chemistry
were investigated. It was found that this method has also been used in fluorescent
microscopy by performing the click reaction directly in the cell monolayer. Working with
our medicinal chemist collaborator who is responsible for the synthesis and development
of the amidine scaffold compounds, she was able to manufacture both an active and an
inactive compound that were appended with the functional groups necessary for the click
reaction to occur. This allowed for the design of experiments where the click reaction
could be performed in combination with staining for VEEV E protein and double stranded
RNA. While it is true that these compounds are able to inhibit the formation of dsRNA
due to their antiviral activities, if used for a short enough time, in this case only 30
minutes, we hypothesized that some replicative activity would remain. This experiment
allows for the direct determination of compound localization in infected cells and can
determine if they associate closely with the sites of viral replication. We hypothesized
that the effective antiviral compound, 3260, would colocalize significantly with dsRNA,
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which is a readout for the localization of viral replication, and that the ineffective
compound, 3261, would be dispersed throughout the cell. Unfortunately, these
experiments proved inconclusive, as the primary difference that was seen between the
two compounds was that the compound that lacked antiviral effects, compound 3261,
appeared to be unable to enter cells at the same rate as the effective antiviral
compound, 3260. Also, further experiments should use a different marker for the
replicase complexes such as nsP2, as even with the short treatment times used there
was a significant reduction in dsRNA staining.
While the results from these microscopy experiments were inconclusive, they
resulted in the development of several new tools for further experiments. First, the click it
reaction was successfully performed on a cell monolayer, and if the L-AHA or other
metabolic labeling can be optimized, these can be combined to great effect. Second,
these experiments led to the optimization of the use of a dsRNA antibody. This antibody
is highly useful as it only stains those cells that are undergoing active viral replication,
compared to cells that express viral protein. This antibody can also be used for
colocalization studies to identify the loci of viral replication within infected cells.
The inconclusive results of the click experiments led to the work developing an
expression system of VEEV nsP2 in E. coli. As outlined above, it was determined that
the N terminal domain of the protein could be expressed in a soluble manner when fused
to a SUMO tag. However, this took quite a bit of optimization of both the constructs and
expression system. The first attempt was made using nsP2 and 4 fusion constructs.
These constructs were readily expressed at high levels but were never able to be
expressed in a soluble form, and refolding these proteins was also unsuccessful. Even in
the Origami strain of E. coli which is designed for the expression of proteins that contain
disulfide bonds and that typically don’t fold correctly in expression vectors, this construct
remained insoluble and disordered.
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This resulted an impasse until we incorporated the SUMO tag. This tag proved
quite helpful in the expression of this protein. The resulting truncated protein constructs
were produced in the soluble fraction of E. coli Rosetta at high concentrations. However,
when this tag was used with full length nsP2 protein and not the truncated construct, it
remained insoluble. If the full length nsP2 is required for future experiments, further
optimization of this expression will need to be carried out. NsP4 was also expressed in
this same system with a SUMO tag, and it too remained insoluble.
Additionally, the SUMO tagged nsP2 truncated construct had some issues with
its purification. As shown, the complete construct can be readily purified using Ni
chromatography. However, upon digestion with the SUMO protease, there is significant
loss of protein sample, indicating that either the digestion, or the purification step
performed to remove the tag need additional optimization. One way that this may be
improved could be to incorporate a different protease site, such as an EK site, between
the tag and nsP2. The use of a different cleavage method may result in a higher fidelity
reaction. Different proteases also have different reaction conditions which may prove
more suitable for our protein constructs, and result in less loss due to degradation. Also,
a portion of the Ni chromatography purified protein was submitted for HPLC purification.
Interestingly, despite a large protein input there were no peaks indicating proteins
release from the column, and this was confirmed using the Bradford reaction. If HPLC is
to be performed again, it is likely that the protein is binding to some part of the column,
and so a different matrix types should be investigated. This protein construct may also
have general issues of stability due to its nature as an incomplete truncated peptide.
This would make slow purification schemes difficult. This should be examined further.
Lastly, the SUMO containing protein construct can be used as is for many
different assays, such as surface plasmon resonance, which allow for the measurement
of binding of the antiviral compounds and the protein construct. Pilot studies were
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performed using the OpenSPR platform from Nicoya, but unfortunately the sensitivity of
the assay was poor, leading to inconclusive data. This is most likely due to the size of
the antiviral molecules, as they are quite small, making the detecting of binding more
difficult that with larger interactors. If these experiments are to be continued, then further
work to increase the sensitivity of the assay should be performed. Such as by using
various treatments to increase the amount of protein construct immobilized on the chip,
or by immobilizing the small molecules on the chip and associating the protein construct.

Conclusions
Though this work attempting to detect and characterize predicted binding
between the VEEV nsPs and the amidine scaffold was unsuccessful, it did lead to
several useful experimental developments. First, the use of click chemistry in assays
using both metabolic labeling of proteins and fluorescent microscopy was developed.
While this chemistry did not prove useful for the experiments described here, these
assays have many potential uses both monitoring the synthesis and localization of
proteins as well as compound localization. There are also potential uses of this
chemistry for directly purifying labeled proteins and compounds from cells and complex
mixtures and extracts. Several additional tools were developed in tandem with these
assays, including the use of a double stranded RNA antibody to track viral replication,
and the novel amidine compounds that have click moieties that have potential to be used
in many different experiments for both detection and purification. Second, an expression
system for the N terminal domain of nsP2 was developed. This protein construct can be
produced in large amounts as a soluble protein. This expressed protein is then readily
purified by Ni chromatography. This system is ready for use in further biochemical
assays.

106

CHAPTER 4
THE USE OF AMIDINE COMPOUNDS TO CHARACTERIZE A REGION OF
UNKNOWN FUNCTION IN VEEV NSP2
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Overview
While antiviral drugs are researched primarily for their potential uses as
therapeutic compounds, these compounds can also be used in viral research in a variety
of ways dependent on their mechanisms of action. One way that these molecules can be
utilized is to probe viruses for novel biological functions that have yet to be described. In
this chapter, the amidine family of compounds characterized in chapter two has been
used to probe the biology of VEEV. In this chapter the isolation and sequencing of
viruses that resist the effects of these compounds will be discussed. Then these isolates
will be used to characterize the function of an N terminal region of the viral nsP2, which
previously has not been characterized and lacks designated functions.

Introduction
Despite the apparent simplicity of many viruses, the study of their biology can be
quite complex. This is due to several factors, such as the uniqueness of many viral
proteins making the use of homology modeling and functional prediction difficult, as well
as the fact that viruses are dependent on cellular processes for many parts of their life
cycles, meaning that functional assays of the viral proteins may not reveal all of the
functions that they perform. Many viruses are also incredibly efficient in the use of their
genetic material, generating proteins that are multifunctional, with many interacting
domains. The result of this is that even many well studied viruses have portions of their
genomes and proteins that have yet to be functionally characterized. This includes
alphaviruses. These viruses were first isolated in the 1930s26,188–190 and have been
thoroughly studied since, yet many parts of their proteins remain enigmatic. This
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difficulty in characterizing these regions necessitates the development of novel ways to
probe viral biology in addition to traditional biochemical and virological methods.
One way that viruses are characterized in our lab is by using the antivirals that
have been developed with our collaborators to perturb the viral life cycle. Due to their
rapid mutations rates191 RNA viruses will often escape treatment with any antiviral
compound, leading to generation of resistant populations that contain mutations in their
genomes192. These mutant viral populations can then be plaque purified, and their
genomes examined for mutations. In this work the Oxford Nanopore system has been
utilized for sequencing of resistant viral isolates. This system is advantageous due to the
small amount of starting material that it requires, as well as the fact that viral RNA can
be sequenced directly.
Viruses that were resistant to the amidine family of compounds described in
chapter 2 were isolated. After sequencing of these mutant populations, it was found that
these viruses had mutations that were localized in the N terminal region of nonstructural
proteins (nsP) 2. It was surprising to find mutations in this region because it currently
lacks any predicted or described function.
NsP2 has been characterized as both the viral helicase protein as well as a
cysteine protease88,96,98,162,193. However, a large portion of the N terminal region remains
undefined. There has been some progress in solving the structure of this protein using
X-ray crystallography, with the C terminal protease region being solved in Venezuelan
equine encephalitis virus (VEEV), and recently the N terminal half of the protein was
crystalized from chikungunya virus (CHIKV)98,193,194. However there has yet to be a
structure solved for the entire protein. The structure of CHIKV nsP2 indicates that the
helicase and its accessory domains take up a large portion of the N terminal region.
From N to C-terminal these domains are: the N-terminal domain, the stalk domain, 1 B,
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Rec 1, Rec, 2, and the connector domain. The 1 B, Rec 1 and Rec 2 domains are all
involved in the RNA binding and helicase activity of the enzyme. However, the
disordered N-terminal domain and the stalk domain lack known fucntion98. Of the
mutations that occur in nsP2 that result in resistance to compound treatment, the
majority are in the N-terminal and stalk domains, such as those at amino acid position 65
and 102, with some being in the far N terminal portion of the Rec 1A helicase accessory
domain, amino acid 116, far from the helicase active site, and arrayed primarily on the
external faces of the protein.
For the purpose of this work, three viral isolates with mutations that occurred in
nsP2 were selected. These mutants were characterized in a variety of classical
virological methods, investigating their growth, RNA synthesis phenotypes, and protein
expression. Initially, this characterization was carried out using baby hamster kidney
cells, a cell line that has long be used in the study of alphaviruses due its high
susceptibility and permissivity to infection195–197198..
After this initial characterization was completed the potential attenuation of these
viruses was also examined in a neuronal cell model, SH-SY5Y cells. Neurons are a
major cell type targeted by VEEV and are important in its pathology, and the effects of
mutations in the nsPs may vary in these cells when compared to fibroblasts. SH-SY5Y
cells are a human neuroblastoma cell line derived from metastatic cancer199. This cell
model has an active viral response system while still being susceptible and permissive to
infection with multiple viruses200–20237. These cells also have the advantage of being able
to be differentiated into mature neurons203201. These differentiated cells are a reasonable
facsimile of mature neurons in the brain203–205. This phenotype indicates that these cells
provide a readily available, biologically relevant model of alphavirus infection of neurons.
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Materials and Methods
Fibroblast cell culture and viral strains
Baby hamster kidney (BHK) clone 21 cells (ATCC CCL-10) and Vero 76 (African
Green monkey kidney fibroblasts) (ATCC® CRL-1587™) were maintained in Modified
Eagle’s Medium with Earle’s Balanced Salt Solution and L-glutamine (MEM-E, Corning
10-010-CV) supplemented with 10% fetal bovine serum (FBS) (Corning 35-011-CV).
Cells were maintained at 37 C in humidified incubators with 5% CO2. VEEV strain TC-83
(gift of Dr. Connie Schmaljohn, USAMRIID) was used for this study. Infections were
carried out using a virus infection medium (Modified Eagle’s Medium with Earle’s
Balanced Salt Solution with L-glutamine (Corning 10-010-CV), 25 mM HEPES, 10%
FBS)
Undifferentiated SH-SY5Y cells
SH-SY5Y cells are human neuroblastoma cells derived from metastatic cancer
isolated from the bone marrow of a patient. Cells were grown on cell culture treated
plates and maintained in at 37°C 5% CO2. Cells were obtained from ATCC (CRL-2266).
Cells were maintained in EMEM with 15% FBS, 1x penicillin/streptomycin, 2 mM
glutamine. Cells were infected with the same media.
Differentiation of SH-SY5Y cells
Differentiation of SH-SY5Y cells into mature neurons has been well documented
previously200,203,204,206–208. Cell were plated on untreated cell culture dishes (day 0). The
following day (day 1) media was changed to differentiation media 1. Media was changed
on days 3 and 5. On Day 7 cells were split 1:1, all with differentiation media 1. Day 8
media was changed to differentiation media 2. Day 10 cells were split 1:1 onto dishes
coated with extracellular matrix with differentiation media 2. Day 11 media was changed
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to differentiation media 3. Media was changed on days 14 and 17 with differentiation
media 3. On Day 18 cells are mature and ready to use. Differentiation media 1: EMEM
with 2.5% FBS, 1x Penicillin/Streptomycin, 2 mM glutamine, 10 µM retinoic acid
(STEMCELL technologies 72262). Differentiation media 2: EMEM, 1% FBS, 1x
Penicillin/Streptomycin, 2 mM glutamine, 10 µM retinoic acid. Differentiation media 3:
Neurobasal media, 1x B-27, 20 mM KCl, 1x Penicillin/Streptomycin, 2 mM GlutaMAX, 50
ng/mL brain derived neural growth factor (Sigma Aldrich B3795), 2mM dibutyryl cyclic
AMP (Selleck Chemicals S7858), 10 µM retinoic acid. Cells were infected in
differentiation media 3.
Plaque purification of resistant viral isolates
Vero 76 cells were infected with VEEV TC-83 in the presence of 20 µM
CB1000905. Supernatant was collected and then used for plaquing with an agarose
overlay, also with 20 µM CB1000905. Plaques were picked and then placed in virus
infection media to allow the virus to diffuse out of the agarose. These samples were then
used to infect monolayers again under compound selection. This process was repeated
a total of three times.
Sequencing of whole viral genomes with the MinIon platform
Vero 76 cells were infected at an MOI of ten with VEEV TC-83 and treated with
compound CB1000905 at 20 µM. The media was aspirated, and TRI reagent was added
at 300 µL per well and the cells were homogenized by pipetting. The RNA was then
isolated using a ZYMO mag bead RNA isolated kit according to manufacturer’s
instruction (R2101). Ribosomal RNA was depleted from the samples using an NEBNext
rRNA depletion kit (NEB E6310S) according to manufacturer’s instructions. This RNA
was used as input for direct RNA sequencing using an Oxford Nanopore direct RNA
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sequencing kit (SQK-RNA002) according to manufacturer’s instructions. Sequencing
was performed using the Oxford Nanopore MinION platform. Sequences were analyzed
using Integrative Genomics Viewer209–211.
Viral growth kinetics
BHK-21 cells were seeded into 6 well plates at a density of 400,000 per well.
Plates were infected at an MOI of 0.05 with the indicated virus and placed on ice for one
hour to synchronize the infection. Inoculum was 0.5 mL. The cells were washed once
with PBS and warm media was added to initiate the infection. The infection proceeded at
37°C 5% CO2. Supernatant was collected at the indicated times and used for titration by
plaque assay.
For infections of the SH-SY5Y, virus had to be diluted into media corresponding
to the needs of either the undifferentiated or differentiated SH-SY5Y cells. Cells were
grown in 24 well plates and infected at a volume of 300 µL. The virus was diluted into the
corresponding media, for undifferentiated cells EMEM with 15% FBS, 1x
penicillin/streptomycin, 2 mM glutamine was used. For differentiated cells differentiation
media 3 was used. Cells were inoculated at either MOI 5 for single step growth analysis
or MOI 0.05 for multistep growth analysis. The cells were incubated at 37°C 5% CO2 for
one hour. The media was aspirated, and the cells washed with the corresponding media
free of virus. Warm media was added, and this point was considered time zero for the
infections. Supernatant was collected at the indicated times post infection, and these
samples were used for plaque assay titration.
Plaque assay titration
Plaquing for titration of the viruses was carried out on Vero76 cells in 24 well
plates. Cells were seeded at a density of 100,000 per well and allowed to grow overnight
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in complete media. Samples for titration were diluted in VIM (Modified Eagle’s Medium
with Earle’s Balanced Salt Solution supplemented with 25 mM HEPES and 10% FBS).
and vortexed. 167 µL of inoculum was used per well in 24 well plates. Media was
aspirated from the cells and the dilute samples added and then incubated at 37°C, 5%
CO2 for one hour. Plates were rocked initially and after 30 minutes. After one hour the
cells were washed with PBS and overlay was added. For titration methyl cellulose
overlay media was used (EMEM, 10% FBS, 0.7% w/v methyl cellulose, 1x GlutaMAX, 15
mM HEPES). These plates were then incubated at 37°C 5% CO2 for three days, and
then stained and fixed with a solution of 2% paraformaldehyde, 0.8% crystal violet in
ethanol, dissolved in PBS.
Plaque size analysis
To measure the relative size of plaques of the viral isolates the protocol above
was modified. Vero 76 cells were seeded at a density of 400,000 cells per well in six well
plates. Samples were diluted in VIM and 668 µL of inoculum was added per well. Cells
were incubated and washed as above. One mL of overlay media was added per well: 1x
EMEM (Gibco 11430-30), 0.6% agarose (MP Biomedicals 952012), 0.22% sodium
bicarbonate (Gibco 25080-094), 1x GlutaMAX, 1x nonessential amino acids (Gibco
11140050), 1x penicillin/streptomycin (Gibco 15140122), 15mM HEPES, 10% FBS. The
plates were incubated at 37°C 5% CO2 for 2 days and fixed with 4% paraformaldehyde
at 4°C. The cells were then stained with 2% paraformaldehyde, 0.8% crystal violet in
ethanol, dissolved in PBS. The plates were scanned, and the images used for plaque
size analysis and counting using the viral plaque plugin for ImageJ/FIJI212.
Isolation of viral RNA for qRT-PCR characterization
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BHK cells were infected at an MOI of ten. The cells were placed on ice for one
hour to synchronize infection. The cells were washed with PBS and then warm media
was added to initiate infection. The cells were placed at 37°C 5% CO2 for the indicated
times. At the indicated times, the media was aspirated, and TRI reagent (ZYMO R2050)
added at 300 µL per well and the cells were homogenized by pipetting. The RNA was
then isolated using a ZYMO mag bead RNA isolated kit according to manufacturer’s
instruction (#R2101).
cDNA synthesis for qRT-PCR analysis
RNA samples were isolated as described above. Two master mixes were made as
follows:
Master Mix 1:
Reagent

Amount per one reaction (µL)
1
1

10 mM dNTPs (Promega U1515)
Custom primer (10 pmol/µL) or
random hexamer (40pmol/µL)
Nuclease free water

4

Four µL of RNA was added to this master mix and the reaction was heated at 65 C for 5
minutes. The reaction was then chilled on ice for 5 minutes.
Master Mix 2:

Reagent
5X reverse transcriptase buffer
(ThermoFisher EP0743)
SUPERaseIn (Ambion AM2694)
Maxima H Minus Reverse
Transcriptase (ThermoFisher EP0743)
Nuclease free water

Amount per one reaction (µL)
4
0.5
0.5
5
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Ten µL of master mix two was added to each reaction after chilling. The reaction as
gently mixed and then submitted to the following protocol for cDNA generation and
thermal degradation of RNA:

1. 25oC for 5 min.
2. 50oC for 60 min.
3. 85oC for 5 min.
4. 4oC hold

This cDNA was then used for further analysis in qRT-PCR analysis as described below.
Strand-specific quantitative real-time PCR (qRT-PCR) of VEEV RNA
Detection of positive and negative sense, genomic viral RNA was carried out
using a strand-specific qRT-PCR method adapted from Plaskon et al165. Briefly, cDNA
was generated using tagged primers for detecting positive-sense and negative-sense
RNA. The generated cDNA was then used in qRT-PCR using TaqMan chemistry with a
strand-specific primer set.. A fluorescent probe was used for both analyses. PCR
reaction was performed using Fast Advanced TaqMan master mix (Applied biosystems
4444557). PCR cycles were performed according to manufacturer’s instructions. The
primer sequences are given in the following table. Lowercase sequences are additional
sequence added for primer identification, sequences in italics are specific for viral RNA,
and sequences in bold were used to identify only those cDNA sequences that were
produced due to primer binding. All primers and probes were custom ordered from IDT.
Primer
nsP1 positive Tag
nsP1 negative
Tag
nsP1 positive
FWD

Sequence
GGCAGTATCGTGAATTCGATGCCTGACCTGGAAACTGAGACTATG
GGCAGTATCGTGAATTCGATGCGGCGACTCTAACTCCCTTATTG
aataaatcataa CTG ACC TGG AAA CTG AGA CTA TG
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nsP1 positive
REV
nsP1 negative
FWD
nsP1 negative
REV
nsP1 probe

aataaatcataa GGC AGT ATC GTG AAT TCG ATG C
aataaatcataa GGC GAC TCT AAC TCC CTT ATT G
aataaatcataa GGC AGT ATC GTG AAT TCG ATG C
/56-FAM/TCC GTC AAC /ZEN/CGC GTA TAC ATC CTG /3IABkFQ

qRT-PCR analysis of subgenomic RNA synthesis
RNA samples from six hours post infection were used. cDNA was generated
from RNA isolated from infected cells as described above using random hexamer. This
cDNA was then used in a multiplex qRT-PCR with the following primers and TaqMan
probes with TaqMan Fast Advanced master mix. All primers and probes were custom
ordered from IDT.
Primer
Capsid FWD
Capsid REV
Capsid Probe
nsP1 FWD
nsP1 REV
nsP1 Probe

Sequence
GGACGACCCATTCTGGATAAC
CGTTCCACATGACGACTGAA
/5SUN/TCCTTCATT/ZEN/CACACCTCCCAGCAC/3IABkFQ/
CTGACCTGGAAACTGAGACTATG
GGCGACTCTAACTCCCTTATTG
/56FAM/TCCGTCAAC/ZEN/CGCGTATACATCCTG/3IABkFQ

The double delta CT was calculated and used to generate the relative gene expression
that is shown.

Immunoblotting

Whole cell lysate from infected cells was collected by directly lysing cells with
Laemmli buffer in the plate (2% SDS w/v, 10% glycerol w/v, 120 mM Tris-HCL pH=6.8,
bromophenol blue)213. The resulting lysate was homogenized by pipetting. Samples were
loaded into gradient gels for SDS-PAGE (GenScript M00656). Samples were run at
170V until the dye front was run off of the gel. Protein was transferred to a PVDF (Biorad
1620177) membrane using methanol Tris-glycine buffer and a semi-dry blotting
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apparatus, 18V for 35 minutes. Membranes were washed once and blocked with 5% dry
milk in TBS. The membranes were washed five times in TBS-T and then stained with
primary antibody overnight at 4 °C. Anti-nsP2 E3 antibody (purified custom polyclonal
antibody from GenScript) and anti-E protein polyclonal antibody (BEI) were both used at
a 1:1000 dilution in TBS-T. The membranes were then washed five times with TBS-T
and stained with secondary antibody diluted in TBS-T. Anti-rabbit HRP (Santa Cruz
Biotechnology Sc-2054) was used to detect the nsP2 antibody and is used at a final
concentration of 0.01 mg/mL. Anti-goat HRP (SeraCare) was used to detect the E
protein and was used at a concentration of 1:10,000. Actin was stained directly using an
HRP conjugated antibody (CellSignal 8H10D10) final dilution 1:10,000. The secondary
antibody staining is performed for one hour at room temperature. The membranes are
washed six times in TBS-T and developed in ECL reagent for five minutes at room
temperature (ECL reagent A: 2.5 mM luminol, 400 mM P-coumaric acid, 100 mM TrisHCL pH=8.5. Reagent B: 0.02% H2O2, 100 mM Tris-HCl pH=8.5. Mix A and B one to
one for development). The images were collected using an Azure imaging system for
detection of chemiluminescence. For staining of the E protein, the membranes
previously stained for actin and nsP2 were stripped in acid stripping buffer (1% w/v SDS,
25 mM glycine HCL pH=2) for 30 minutes at room temperature with rapid agitation, and
washed twice with PBS, and once with TBS-T before proceeding with blocking and
staining.
Statistics
Statistics were performed in GraphPad Prism version 9. Unless otherwise
indicated significance was calculated using ANOVA with Dunnett corrections for multiple
comparisons. Error is reported as standard deviation. Graphs represent mean values of
the indicated number of experiments.
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Results
Compound resistant viral isolates of VEEV have mutations in nsP2
Previous work with the antiviral compounds in our lab has identified the locations
of mutations that occur in viral isolates that resist compound treatment which were
isolated via plaque purificaiton148. Three isolates were selected that were known to have
mutations in nsP2, to focus on characterizing unknown activities of this protein. After the
initial selection, these viruses were submitted to whole genome sequencing to determine
if there were any additional mutations in their genomes that had not been previously
discovered. This process utilizes a direct RNA sequencing method developed by Oxford
Nanopore for use with their MinION platform.
It was found that mutations occurred in multiple locations in each of the selected
viral isolates. Two of the isolates had single mutations in nsP2 at Y102 and D116. Both
of these isolates also had point mutations in their E proteins. The third selected isolate
had two mutations in nsP2 at both Y65 and Y102. This isolate also had a single point
mutation in the subgenomic promoter region. While this is a noncoding region in the viral
RNA it is highly important due to its regulation of subgenomic RNA synthesis. This led to
the hypothesis that this mutant isolate is likely to have significant alterations to its
expression of the structural proteins. The nucleotide sequence of the area of nsP2 that is
mutated is shown in Figure 18, nucleotide changes are shown in red, and the position of
the nucleotide is indicated. Maps of the viral genome are shown in Figure 19, with each
of the mutations indicated. Table 3 lists the selected isolates with their mutations.
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Figure 18. Single nucleotide polymorphisms of the selected viral isolates in N-nsP2. The
sequences of VEEV TC-83 as well as the three selected mutant isolates are shown. The
mutated nucleotides are shown in red and the poisitons boxed in. The nucloetide
position is below the selected bases. All of the selected amino acid changes are due to
single nucleptide polymoorphisms.
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Figure 19. Maps of the full length genomes of the selected mutant viruses. A) Simplified
map of isolate 82_11_24. Sequencing found a mutation, D116N located in the 1 B
domain in nsP2, and there was an additional point mutation in E1. B) Simplified map of
isolate 81_12_24. Sequencing found a mutation, Y102C located in the stalk domain in
nsP2, and there was an additional point mutation in E2. C) Simplified map of isolate
6_13_25. Sequencing found two mutations, Y65C in the N-terminal domain and Y102C
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in the stalk domain in nsP2. There was an additional SNP in the region corresponding to
the subgenomic promoter.
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Amino
Acid
Position
TC-83
82_11_24
81_12_24
6_13_25

nsP2
Y65

nsP2
Y102

nsP2
D116

------C

----C
C

--N
-----

Sub
Prom
7531A
------T

E2
F410

E1
N20

Short
name

----Y
---

--S
-----

--1124
1224
1325

Table 3. Selected resistant viral isolates. Mutations are as indicated.
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Compound resistant mutant viruses displayed delayed growth in a fibroblast cell
model.
The three mutant viruses were expanded under compound selection to ensure
that the mutations were maintained through passaging. BHK cells were then infected at
an MOI of 0.05 and a growth kinetics assay was performed using plaque assays to
determine viral titer. It was hypothesized that isolate 6_13_25, with the subgenomic
promoter mutation, would have a significant reduction in growth due the predicted effect
this mutation would likely have on structural protein expression. However, the mutant
isolates did not demonstrate a reduction in maximum titer compared to TC-83, Figure 20
A. Instead each virus eventually reached and maintained a titer that was similar to the
parental strain. These mutations did, however, result in delayed growth compared to the
parental control TC-83. Isolates 82_11_25 and 81_12_24 both had delayed viral
production, but quickly caught up to TC-83. 6_13_25 was the most significantly delayed
and took the longest to reach parity with TC-83, Figure 20 A. These results show that the
mutations found in the resistant viral isolates lead to a growth delay, with slower
infection, and production of infectious virus, but not a growth defect in this non-selective
cell line.
While performing the plaque assays for the growth kinetics analysis, plaque
morphology changes were noted in isolate 6_13_25. To examine this in greater detail,
agarose plaque assays in 6 well plates were used, Figure 20 B. This analysis showed
that 6_13_25 did in fact have smaller plaques than the other isolates or TC-83, Figure 20
C. This is not surprising, as the structural proteins, and capsid in particular, are very
important to the biological activities of alphaviruses and are under control of the
subgenomic promoter7,55. The capsid protein is also very important in inducing cytopathic
effect, detected phenotype in plaque assays80. These plaques also had a much tighter
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distribution compared to TC-83 or the two single mutants. This phenotype indicates that
isolate 6_13_25 is significantly attenuated compared to TC-83 and is less fit for cell to
cell spread or cytopathic effect, in addition to the growth defect that it shares with the
isolates that lack the subgenomic promoter mutation. Isolates 81_12_24 and 82_11_24
have more moderate attenuations.
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Figure 20. Mutant viral isolates show delayed growth in a fibroblast cell mode, and
isolate 6_13_25 has decreased plaque size. Three mutant viruses were selected with
the indicated mutations in nsp2. BHK cells were infected at an MOI of 0.05 A) All of the
mutant viruses showed a delay in the production of new infectious virus as measured by
plaque assay. Isolate 6_13_25 showed a larger delay than either of the two single
mutants. Kinetics data combined from two experiments, three biological replicates per
time point per experiment. 48 HPI was only collected from one experiment B)
Representative images of plaque morphology from each of the viruses using an agar
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overlay and staining the monolayers with crystal violet. Representative of three
experiments. C) Quantification of the relative size of the plaques from each virus. The
double mutant shows plaques that are significantly smaller than those of the parental
TC-83 strain. The single mutants show no change. Graph is from one representative
experiment of three. Three biological replicates per experiment. P<0.0001 as calculated
by one way ANOVA.
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Compound Resistant Viral Isolates Show Alterations in Their RNA synthesis
profiles
NsP2 is highly important in the RNA synthesis of alphaviruses, acting as the RNA
helicase of these viruses and having RNA binding activity (described in detail in chapter
1). Having noted a delay in growth of these resistant isolates, it was hypothesized that
this growth delay resulted from a defect in viral RNA synthesis, likely being mediated by
the mutations that occur in N terminal region of nsP2.
Alphaviruses produce both positive and negative-sense RNA for replication82.
These strands are both synthesized by the nonstructural proteins, but this synthesis is
tightly controlled58,59,61,160,214. Thus, the synthesis of these two strands was examined
separately, using a modified RT-PCR that is able to discriminate between the two
different of polarities of RNA.
It was found that both isolate 81_11_24 and 6_13_25 had delayed production of
positive-sense RNA, Figure 21. This was similar to growth kinetics phenotypes. With the
detection of the positive sense RNA being delayed early in infection and catching up to
the parental virus strain by 8 hours post infection. That both of these isolates show this
delay indicates a likely involved of the N terminal domain of VEEV nsP2, as isolate
81_11_24 lacks the significant mutation in its subgenomic promoter. However, only
isolate 6_13_25 showed a significant delay in the synthesis of negative-sense RNA,
Figure 22. This indicates a likely involvement of nsP2 Y65C in the synthesis of negativesense RNA as only this isolate contains this mutation, and this synthesis should not be
affected by the subgenomic promoter.
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The relative expression of the subgenome was also examined, Figure 23. This
was quantified by comparing the ratio of subgenomes to genomes in each of the viral
isolates and TC-83. It was hypothesized that isolate 6_13_25 would have significant
alterations in subgenomic RNA synthesis levels due to the mutation in the subgenomic
promoter. While the other two isolates have point mutations in their glycoproteins, these
proteins are not involved in RNA synthesis, so it was unlikely that the synthesis of the
RNA would be effected. It was found that isolate 6_13_25 had greatly reduced
subgenomic RNA expression, producing virtually no subgenomes at the time point
examined, and the two other isolates displayed similar ratios to the parental TC-83
strain, Figure 23.
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Figure 21. Mutant viral isolates have a delay in positive-sense RNA synthesis. Strand
specific qRT-PCR was performed at the indicated times post infection. Isolates
82_11_24 and 6_13_25 both show reduced levels of positive-sense RNA at two and four
hours post infection. This difference is lost at eight hours post infection, by which time
every strain has reached the same level of RNA Data from one representative
experiment of three. Three biological replicates per experiment. *p<0.05, **p<0.01,
***p<0.001 as measured by one way ANOVA.
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Figure 22. Isolate 6_13_25 has a delay in negative-sense RNA synthesis. Strand
specific qRT-PCR was performed, and the amount of negative sense viral RNA
quantified. Isolate 6_13_25 was found to have reduced negative sense RNA at two and
four hours post infection. This difference was no longer present at eight hours post
infection. Data from one representative experiment of three. Three biological replicates
per experiment. * p<0.05, **p<0.01 as measured by one way ANOVA.
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Figure 23. Relative expression of the subgenomic RNA compared to genomic RNA.
Expression of capsid RNA was quantified relative to the expression of nsP1. This
relative expression was then compared between the mutant viral isolates and TC-83.
Only isolate 6_13_25 is significantly different from TC-83 with a ratio of one half that of
the parental strain, indicating there is little to no subgenomic expression at this time.
Data from one experiment, three biological replicates. *p<0.05.
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Viral Isolates with mutations in nsP2 have altered protein expression profiles
Having investigated both the growth and RNA synthesis profiles of these
compound resistant viral isolates, the next step was to examine their protein expression.
The finding that two of these isolates had altered RNA synthesis led to the hypothesis
that they would have similar delays in the expression of the viral proteins, indicating that
a delay in replication of the viral RNA was leading to the delay seen in viral growth
kinetics. In addition, it was expected that there would be marked decrease in the
structural proteins of isolate 6_13_25 due to large decrease in its transcription of the
subgenomic RNA. While there was not a statistically significant delay in RNA synthesis
in isolate 81_12_24, it did have a delay in growth kinetics and displayed a trend of
reduce positive-sense RNA synthesis at early times points, so it was expected to show a
delay in protein synthesis as well.
To examine viral proteins synthesis, immunoblotting was performed. Nsp2 was
used as a marker of the expression of the viral nonstructural gene and has been
previously used by our lab in this manner66. The E protein was used as a maker for the
expression of the viral structural protein, the antibody used here stains both the E1 and
E2 proteins. Beta actin was used as a loading control, and its intensity was used to
quantify the relative expression of the viral proteins across the different samples.
Protein expression was examined in BHK cells, which were infected at an MOI of
ten and then lysed at the indicated times post infection. Representative blot images are
shown in Figure 24. NsP2 had delayed expression in all of the resistant isolates, and
was detected at lower levels than TC-83 until eight hours post infection, at which time
the expression of nsP2 begins to match that of the parental strain, Figure 25 A. At ten
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hours post infection, the slowest of the mutant viruses, isolate 6_13_25, has increased
levels of nsP2 compared to TC-83. If 6_13_25 is less cytotoxic, then there would be
more live infected cells at this later time point post infection, which would leave more
infected cells to by lysed and used for detection. At this time post infection there was no
staining of any forms of the nonstructural polyprotein.
When examining the expression of the E proteins, the hypothesis about isolate
6_13_25 was correct, this isolate had a significant reduction in expression of the protein
at 10 hours post infection, Figure 25 B. This was true for all cleavage forms of the E
proteins. It was unclear from their sequences if the other two isolates would have any
alterations in their expression of the structural proteins. While both 82_11_24 and
81_12_24 had statistically significant differences in their expression of the E proteins at
ten hours post infection, these differences are small in magnitude and not likely
biologically significant. None of the isolates had significant changes in their expression at
8 hours post infection, however isolate 6_13_25 had a similar trended towards reduced
expression compared to TC-83.
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Figure 24. Representative Western blot images examining viral protein expression. Cell
lysate was collected and used for Western blotting at the indicated times post infection.
Lysate was probed for nsP2 and E protein as indicated, and actin was used was an
internal loading control. Labels: U=uninfected, 1124=82_11_24, 1224=81_12_24,
1325=6_13_25. All of the mutant viruses display a delay in nsP2 production, similar to
their delay in growth kinetics. However, only the double mutant, 1325, showed a
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reduction in E protein synthesis. Representative images of one experiment of three.
Each experiment had three biological replicates per virus and uninfected control.
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Figure 25. Quantification of viral protein expression. Using densitometry, the relative
expression of nsP2 and the E protein was quantified. A) Quantification of nsP2
expression at the indicated times post infection. All mutant isolates show delayed
expression, with less nsP2 present than in TC-83 at three and five hours post infection.
By eight hours expression has caught up, and this is maintained at ten hours. B)
Quantification of E protein expression. There is no significant difference between the
viruses at eight hours post infection, however at ten hours post infection both isolate
6_13_25 and isolate 82_11_24 mutant show significant reductions in E protein
expression compared to TC-83. Combined data from three experiments. Three biological
replicates per group *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 as calculated using
one way ANOVA.
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Growth of VEEV TC83 and mutant isolates in a neuronal cell model
While fibroblasts have historically been the cell of choice for much alphavirus
work, these cells are only a model of the initial stages of infection. The severe pathology
of VEEV, encephalitis and other neurological effects, primarily occurs in neurons and
related cells and not in fibroblasts. Thus, it was decided to examine the mutant viral
isolates for attenuation in a model of neuronal cells.
The SH-SY5Y cell line was selected for several reasons. When maintained in cell
culture they have a neural progenitor cell like phenotype and can be maintained for
several passages which is a significant advantage over other types of neural cell culture.
These cells can also be differentiated into a neuron like phenotype if given the correct
additives and media203. These neuron like cells have processes and are positive for
markers of mature neurons205.
When growth kinetics were examined in undifferentiated SH-SY5Y cells, the
delay in viral growth was reduced, Figure 26 A. While isolate 6_13_25 displayed a delay
in growth, while still eventually reaching parity with TC-83, isolates 81_12_24 and
82_11_24 did not display significant differences from TC-83. This indicates that in these
undifferentiated neuronal cells, the reduction in the structural genes or delay in
subgenomic RNA synthesis is playing a significant role in the delay in viral growth, while
the N terminal region of nsP2 appears to be less important. However, in the
differentiated cells all of the mutant viral isolates had delayed growth and isolate
6_13_25 never reached parity with TC-83, ending the time course with a half log
reduction in maximum titer, Figure 26 B. This shows that in these differentiated cells,
both the N terminal region of nsP2 and the effects of the subgenomic promoter region
are important to normal virus growth. The normal synthesis of the subgenome and the
structural proteins is also important to reaching normal titers in these cells. This indicates
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that the differences in physiology of the differentiated cells leads to different restrictions
on viral growth. SH-SY5Y cells have been used as models for many different types of
neural pathologies199,200,202,205,207, and these cells display a phenotype that is similar to
mature neurons after differentiation. This results in many changes to the metabolism and
biology of these cells that could restrict viral growth. This includes the production of
various neuron specific biological markers as well as neurotransmitters, as well as a
slowing and eventual stop of the cell cycle where these cells no longer divide. Any one
of or combination of these changes may result in restricted and slow viral growth. For
example, due to this slowing of the cells cycle there will be less resources present in the
cell for the virus to use to fuel its own replication leading a slow in its replication. It is also
possible that any of the many upregulated neural genes may also have off target effects
that restrict viral replication.
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Figure 26. Compound resistant mutant viruses have delayed growth in a neural cell
model. A) Undifferentiated SH-SY5Y cells were infected with the indicated viral strains at
either 0.05 or 5 MOI. Supernatant was collected at the indicated time points and
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replication measured by plaque assay. In undifferentiated neural cells, there was little
delay seen in the single mutants. However, growth of isolate 6_13_25 still showed a
delay in growth. B) Differentiated SH-SY5Y cells were used in the same experiment as
A. In this case all of the mutant isolates showed a delay in growth, and isolate 6_13_25
was generally attenuated as well, with a final titer fivefold less than the parental strain.
Graphs are of individual experiments that were performed once. Three biological
replicates per time point collected.
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Discussion
While alphaviruses are well studied, there remain portions of their genomes and
proteins that lack described function and have remained difficult to characterize using
typical methods of investigation. In this chapter viral isolates that resist treatment with
antiviral compounds identified and derived in our lab were used as a method of viral
biology characterization. Through the sequencing of these isolates, mutations were
confirmed to be in an undescribed region of VEEV nsP2. This allowed for
characterization of these mutants as a proxy for determining the function of the region.
Each of the isolated mutants had and additional mutation outside of the nsP
encoding regions. Isolates 81_12_24 and 82_11_24 both had a single point mutation in
their E proteins and isolate 6_13_25 had a mutation in the subgenomic promoter region.
While the mutations in the E proteins had no obvious effect in our characterization of
these isolates, the subgenomic promoter mutations had significant effects. This mutation
resulted in decreased subgenomic RNA synthesis structural gene expression. This
mutation is likely involved in small plaque phenotype only seen in insolate 6_13_25, as
well its increased attenuation in growth kinetics compared to the other isolates.
The region of nsP2 that was mutated appears to be important in normal RNA
synthesis. As two of the isolates have delayed synthesis of positive-sense RNA. It is
hypothesized that due to the location of these mutations in an external face of the
protein, and far from the active helicase sites, that this region is likely involved in protein
interactions that stabilize the nsP complex during replication. This delay in RNA
synthesis also resulted in a delay in the expression of the viral nsPs, as indicated by
reduced and delayed expression of nsP2. This delay would have cascading effects
during infection. Due to its importance as a major driver of viral RNA synthesis, a
slowing of nsP2 expression would delay RNA replication, which would result in a vicious
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cycle of reduced RNA leading to longer delays in protein synthesis. And this would, in
turn, explain why these viruses have delayed replication. The fact that the viruses
overcome this attenuation later in infection to reach similar maximal titers as TC-83 is
explained by the exponential reduction of these molecules. Eventually so much nsP2
and RNA are created that the viral replication and production machinery, as well as the
ribosomes, become wholly saturated, and further acceleration is not possible.
In addition to the work characterizing RNA replication, protein expression, and
growth kinetics in fibroblast cells, a more restrictive neural cell line was used. SH-SY5Y
cells are advantageous as a model because unlike other neuronal cell lines, they can be
maintained for several passages in cell culture when kept in their immature state. This
immature state is similar to neural progenitor cells. They can also be differentiated,
commonly using retinoic acid, to mimic a mature neuron cell type.
There was no increase in attenuation when the mutant viral isolates were grown
in the undifferentiated SH-SY5Y cells and in fact, they were more similar to TC-83 than
in the fibroblasts. This is an interesting phenotype that deserves further study. It is
possible that his has to with their state along the epithelial-mesenchymal axis, as these
cells were derived from metastatic neuroblastoma that was extracted from bone marrow.
When these viral isolates were examined in differentiated SH-SY5Y cells, the
attenuation was increased compared to TC-83. The growth delay was more significant
and isolate 6_13_25 had a reduced maximum titer as well. This may be due to an
increased basal activation level of antiviral signaling in the mature cells. However, as this
is quite different from the undifferentiated cells, it is likely that this restriction is due to a
change relating to the maturation of the neurons themselves. These cells have been
found to behave in many ways like mature neurons, and it is possible that one of the
many biochemical pathways that they activate results in the restriction of viral growth.
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This indicates that the N terminal region of nsP2 is important for normal replication in
these cells and should be investigated further for potential interactions with molecules
that are expressed in these differentiated cells but not in undifferentiated SH-SY5Y cells.

Conclusions
From the work that has been presented here it is clear that mutations in the N
terminal region of VEEV nsP2 are detrimental to production of new infectious virus, and
that this results from a delay in RNA synthesis, leading to a delay in the production of the
viral nonstructural proteins. While a detailed mechanism remains unclear, this region
appears to be important to the RNA synthesis of the virus. The current hypothesis is that
the mutations are disrupting the protein/protein interactions that help to form and
stabilize the mature replicase complex, particularly between nsP2 and nsP4. This is due
to these mutations being far from any sites known to be involved in the helicase or RNA
binding activities of nsP2, and their localization to sites that are largely on external faces
of the protein structure.
This N terminal region of nsP2 is also important for replication in differentiated
SH-SY5Y cells, but not in undifferentiated cells. This indicates that this region is likely to
interaction with pathways or components of the mature cells that are nor expressed in
the neuroprogenitor like cells. This should be further investigated, looking for potential
interaction partners in the cell, as well for pathways that are altered in these cells upon
infection.
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CHAPTER 5
DISUCSSION AND FUTURE DIRECTIONS
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DISCUSSION
This work has investigated the mechanism of action and interactions of a novel
antiviral amidine scaffold with Venezuelan equine encephalitis virus (VEEV). These
compounds were also used to generate mutant virus populations that were used to
investigate heretofore unknown aspects of VEEV biology. This work has shown how
these compounds have promise both as potential therapeutics for VEEV induced
disease, as well as for probing biological activities of uncharacterized portions of the viral
genome. In this manner, these compounds have future usefulness both as potential
treatments, as well as in the development of further compounds targeting novel
biological activities that they can be used to detect and characterize.
The compound scaffold was characterized through the methods described in
chapter two. It was found that these compounds specifically and efficiently inhibit the
synthesis of VEEV RNA during infection, and that this activity is maintained in a cell free
system. The specificity of these compounds is highly desirable, as it means there are
less likely to be off target effects when they are moved to more complex systems such
as animal models. The RNA synthesis inhibitory effect of these compounds is also novel
in the development of anti-VEEV molecules, as there are no other direct RNA synthesis
inhibitors under investigation outside of our research group and collaborators. This is
contrasted to nucleoside analogs, which are popular drug targets, but only inhibit viral
RNA synthesis indirectly.
This work characterizing the antiviral activity of these compounds led to our
hypothesis that there is a direct interaction between the compounds and the viral
proteins. This is due to the fact that compound ML336 maintains its effectiveness in a
cell-free RNA synthesis assay. While this assay is not able to fully confirm an interaction
between the viral proteins and compounds due to the inclusion of some cellular
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components, its minimal nature makes it more likely that the compounds are directly
interfering with the viral proteins. This led to investigation described in chapter 3,
attempting to identify and characterize this proposed interaction between the amidine
compounds and the VEEV nsPs.
Unfortunately, it was not possible to confirm or deny the existence of this
interaction, as the data obtained from the experiments looking to detect this binding were
largely inconclusive. However, there were several advances that were made through this
work. First, a reliable method of expressing the N terminal domain of VEEV nsP2 was
developed. While this protein was not able to be used for the full range of
characterization studies desired, this system has been well optimized for expression,
and large parts of its purification. Adding a useful tool for future binding kinetics assays,
as well as biochemical experiments examining the effects of these compounds on the
enzymatic activities of the N terminal region of nsP2.
Additionally, a technique using fluorescent microscopy with a double stranded
RNA antibody as a readout for active viral replication was performed for the first time in
our lab. This tool allows for the detection of both localization of the replication activity of
this virus in infected cells, and quantification of how many cells are undergoing active
viral production at any given time during infection, as opposed to cells that may no
longer contain actively replicating virus, but still express viral proteins. For this same
assay, click chemistry compatible compounds were developed by our medicinal chemist
collaborator, opening up many new avenues for compound manipulation. The modified
functional groups of these compounds allow for a variety of detection methods, as
described here, as well as purification of the compounds from complex mixtures, as has
been previously performed with labeled proteins215, depending on the desired use.
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In addition to being useful for therapeutic development, antiviral compounds can
also be used as chemical probes of viral biology. These compounds can be used to
generate resistant mutant viral isolates, and these mutations can then be mapped to the
viral genome, indicating the region(s) that are important in the activity of the compounds.
This is useful from both a drug mechanism standpoint as well as a viral biology
standpoint. For example, in this work it has been shown that the amidine antiviral
scaffold functions to inhibit viral RNA synthesis. This means that any mutations that
occur in the viral genome which confer resistance to drug treatment are in areas that are
likely to be highly important for the synthesis of viral RNA. When these experiments
were performed using the amidine scaffold compounds, it was found was that the
resistance mutations consistently mapped to the N terminal domain of VEEV nsP2, a
region of currently undescribed function.
The localization of mutations to this region is not altogether surprising, as nsP2 is
highly important in viral RNA synthesis, acting as the viral RNA helicase. NsP2 is also
responsible for the normal cleavage of the polyprotein, which regulates RNA synthesis
during viral infection216–219. As the implicated region lacked a specific function it was
hypothesized that it was involved the normal synthesis of viral RNA. Due the location of
the mutations on an external face of the protein, as well as the mutations being found
primarily in less ordered regions, this activity was predicted to be mediated by interfering
with the protein/protein interactions of the replicase complex and destabilizing these
interactions.
A group of mutant isolates was selected and submitted for further
characterization studies. First, it is important to point out that these mutations were not
found in detectable levels in unselected viral populations, indicating that these mutations
are likely to be detrimental to the virus in the absence of selection by the compound.
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Initially these viral isolates were examined in a growth curve using highly permissive
fibroblast cells, this experiment showed that the compound resistant isolates had
delayed growth compared to the parental VEEV strain used, but they did reach the same
peak titers late in infection. This result was then mirrored in their RNA synthesis profiles
with the mutants having delayed synthesis of both positive and negative sense genomic
RNA.
Three mutant viruses were selected for further characterization. Two isolates
contained only single point mutations in nsP2 as well as a single point mutation in their E
proteins. These isolates were predicted to be attenuated and display alterations in their
RNA synthesis. A third isolate had a double mutation in nsP2 as well as a point mutation
in its subgenomic promoter region. This isolated was predicted to be highly attenuated
due to expected changes in the synthesis of its subgenomic RNA, and it was unclear
how the mutations in nsP2 would combine with this to effect RNA synthesis and viral
replication.
Each of these viruses was attenuated in fibroblast cells, having delayed growth
compared to the parental strain. As predicted the isolate containing the mutation in the
subgenomic promoter was strongly attenuated, with the other two isolates having
intermediate phenotype. However, it was surprising that each these isolates eventually
reached parity with the parental strain and had no reduction in maximum titer. Similar
phenotypes were seen when RNA synthesis was examined, and as predicted, the
isolate with the subgenomic promoter mutation had a decrease in subgenomic RNA
synthesis that the other two isolates did not display. The effects of these mutations on
protein expression were slightly different, each of the isolates had a significant delay in
the production of the viral nsPs and did not reach parental expression levels until eight
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hours post infection. As expected, only the subgenomic promoter mutation had an effect
on the synthesis of the structural proteins.
When combined this data indicates that mutations in the N terminal region of
nsP2 lead to delays in RNA synthesis leading to delays in nsP expression. As the nsPs
are responsible for the replication of the viral RNA, these effects compound during
infection, slowing viral replication, and leading to the delayed growth that was seen.
However, as there was no loss in titer, and expression levels of both RNA and protein
reach parity with TC-83 later in infection, these effects are overcome. This is most likely
due to the nature of the exponential production of viral materials during infection. Even
though the log phase growth of the virus is delayed, the viruses are still able to produce
enough of their components over time to saturate their replicative systems as well as
those of the cell, at which point no more acceleration of replication is possible. This
results in the maximum titer being achieved, even though it takes longer to reach. A
model outlining this hypothesis can be found in Figure 27.
These phenotypes had all been examined in a highly permissive fibroblast cell
line. These cells lack the ability to activate their interferon system and so are unable to
enter an antiviral state. It was hypothesized that the mutant viral isolates would be
increasingly attenuated in a cell system that could activate the antiviral response, so a
second cell line was selected to examine this. SH-SY5Y cells were selected. These cells
have a neural progenitor cell like phenotype and can also be differentiated into a mature
neuron like state, making them an excellent model of VEEV infection in neurons, a
significant site of pathology in the host220,221.
The growth kinetics of the mutant viral isolates were examined in both the
differentiated and undifferentiated cells. In the immature cells, the growth delay was less
significant than that seen in the fibroblast cells. Only the isolate containing the
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subgenomic promoter mutation was found to have a significant delay compared to TC83 and as before it still reached parity alter in infection. However, in the differentiated
cells each of the isolates was significantly attenuated, and the isolates with the
subgenomic promoter mutation had a final titer reduction of fivefold. This difference
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Figure 27. Working model of the effects of mutations in the N-terminal region of VEEV
nsP2. A) Early in infection the nonstructural polyprotein is synthesized from the genomic
RNA. However, due the presence of mutations, the protein interactions have reduced
stability, resulting in a significant reduction in the number of active complexes. This
reduces the rate of viral RNA synthesis. B) As infection proceeds to later time points, the
amount of nsPs synthesized increases. This increases the number of complexes that
form despite the reduction in interaction stability. This leads to an increase in the rate of
viral RNA synthesis, eventually reaching the maximum rate seen in infection with the
parental TC-83 strain.
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between the differentiated and undifferentiated cells implies that the N terminal region of
nsP2 is likely important to the normal replication of VEEV in mature neurons but not in
other neural derived cells, such a neural progenitor cells. The differentiated cells go
through significant physiological changes during the maturation process leading to a
host of phenotypes that make them useful models for neurological disease200,202,207,221.
This includes the production of neurotransmitter, the formation of neural processes, and
loss of cell cycling behavior. Any one or multiple of these changes could lead to more
restricted replication of VEEV. Of particular interest is the way that the senescence of
these cells may restrict the amount of resources available for viral replication, which is
likely to perturb the ability of the virus to replicate as quickly as it would in the dividing
undifferentiated cells.
To summarize the work presented in this dissertation, the amidine scaffold
compounds developed by our lab for the treatment of VEEV are highly effective and
specific at inhibiting VEEV RNA synthesis. This activity is maintained in a cell-free
system and has no effect on cellular RNA. These compounds are currently being used
as the foundation for pretherapeutic drug discovery and development with collaborators.
These compounds are predicted to interact with the nsPs of VEEV. While this interaction
remains unconfirmed, several useful biochemical assays were developed, and can be
used for further characterization of both antiviral compounds and viruses. A system was
also developed for the recombinant expression of the N terminal region of nsP2, and this
system is ready for use in biochemical and pharmacological assays. The amidine
compounds were also used to derive resistant viral isolates that were used to
characterize the N terminal region of VEEV vsP2. It was found that this region is
important to the synthesis of viral RNA, and that its perturbation leads to a delay in viral
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growth. This region is also important in the infection of differentiated neurons, but not
undifferentiated neuronal cells. The mechanism of this phenotype remains unknown.

FUTURE DIRECTIONS
The work presented here has left several unanswered questions that need to be
further examined and opened new questions.
First, it remains unclear how and if the amidine scaffold compounds are
interacting with the proteins of VEEV. While the sequencing results from chapter 4
clearly indicate that mutations occur in a predictable manner to escape compound
treatment, it has yet to be shown that the compounds and viral proteins directly interact.
In chapter 3 several methods that were used to attempt to describe this interaction were
summarized. However, no conclusive results were obtained. The primary way that this
work should be continued is continuing to pursue the use of ectopically expressed
protein for use in biochemical and pharmacological assays.
The production of the N terminal region of nsP2 in a soluble form has been well
optimized as has its initial purification. Further work remains in optimizing the cleavage
of the SUMO tag from the construct, which will be necessary for any functional assays to
be performed, such as helicase activity assays. The currently expressible protein is
already usable in many types of binding assays such a microscale thermophoresis or
surface plasmon resonance. While each of these assays requires highly pure sample,
tag removal is not necessary so the current construct can be used. Pilot studies using
SPR have been performed, however sensitivity was poor and further optimization of this
assay is required.
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Secondly, the work with the resistant viral isolates has shown that as expected,
the N terminal region of nsp2 appears to be important to viral RNA synthesis. However,
each of the isolates tested had an additional mutation. The N terminal region needs to
be isolated to confirm that these phenotypes are due to the mutations in this region. To
do this, a reverse genetic system can used. Plasmid based clones of TC-83 are
available, and the desired mutations can be inserted using site directed mutagenesis.
With the use of in vitro transcription these plasmids can be transfected into cells and
virus generated with the desired genotypes. These viruses can then be submitted to the
same experimenters as already performed with the mutant viral isolates. This type of
system can also be used to isolate the double nsP2 mutation seen in one isolate, which
was confounded by the presence of a mutation in its subgenomic promoter.
Finally, the work with the resistant viral isolates in neuronal cells indicated that
the N terminal region of VEEV nsP2 is important for the normal infection of differentiated
neurons. The effect of mutating this region was more significant in these cells than an
either fibroblasts or undifferentiated neuronal cells. This lead to the hypothesis that a
feature unique to the differentiated neural cells was involved in this enhanced restriction
on viral replication. This should first be investigated by examining the differential gene
expression of the differentiated and undifferentiated cells to determine their differences
in gene expression that may explain this alteration in sensitivity to viral infection. Further
transcriptional changes in response to infection can then be determined by performing
single cell sequencing and isolating those genes that upregulated in the infected but not
uninfected cells, to characterize the response to infection. Ideally, there will be known
antiviral signals or vial interactions that can be pursued in further, more detailed
experiments. If not, there are a variety of ways that protein interactions can be predicted
to lead to potential genes of interest.
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